



## OUTPATIENT CANCER DRUG BENEFIT PROGRAM

Ministerial Approval: June 20, 2014

The Alberta Health Services shall provide cancer drugs specified in the Outpatient Cancer Drug Benefit Program, at no charge, to eligible residents for the treatment of cancer as outlined in Ministerial Order # 10/2009

### DEFINITIONS

"Eligible resident" means a person who:

1. holds a valid certificate of registration under the *Health Insurance Premiums Act*,
2. is registered in the Cancer Registry with a disease classified in the *International Classification of Diseases for Oncology*, and
3. requires cancer drugs to treat cancer.

"Cancer Pharmacy" means the pharmacy at the Cross Cancer Institute and the Tom Baker Cancer Centre, and other pharmacies operated by or for cancer centre as outlined in Ministerial Order #10/2009

Subject to this Ministerial Order, Cancer Drugs may be:

1. administered directly to in-patients or out-patients of Cancer Centres, or
2. sent to:
  - i) other health care providers; or
  - ii) a pharmacy that is owned or operated by or for Alberta Health Services, for administration or provision directly to the patient.

### GROUP 1 DRUG LIST

Cancer Drugs in group 1 of the Schedule may be dispensed by a Cancer Pharmacy pursuant to a prescription written by a person who is authorized by the Alberta Health Services to prescribe Cancer Drugs and who is a physician, a regulated member under the *Health Professions Act* authorized to prescribe drugs, or a person authorized to prescribe drugs pursuant to another enactment.

### GROUP 2 DRUG LIST

Cancer Drugs in group 2 of the Schedule may be dispensed by a Cancer Pharmacy only if the initial prescription is written by a Cancer Centre Medical Staff member, but a subsequent prescription for the same patient may be written by a person authorized by Alberta Health Services to prescribe Cancer Drugs and who is a physician, a regulated member under the *Health Professions Act* authorized to prescribe drugs, or a person authorized to prescribe drugs pursuant to another enactment. The following physicians from the CCI and TBCC are automatically named on all Group 2 drugs contained on the following pages: (CCI: Dr. Naveen Basappa, Dr. Sanraj Basi, Dr. Andrew Belch, Dr. Charles Butts, Dr. Quincy Chu, Dr. Neil Chua, Dr. A.L.A. Fields, Dr. Amelie Fontaine, Dr. Maria Ho, Dr. Anil Joy, Dr. Karen King, Dr. Sheryl Koski, Dr. John Mackey, Dr. Judith Meza-Junco, Dr. Karen Mulder, Dr. Scott North, Dr. Julie Price Hiller, Dr. Lalit Saini, Dr. Randeep Sangha, Dr. Michael Sawyer, Dr. Andrew Scarfe, Dr. Michael Smylie, Dr. Jennifer Spratlin, Dr. Minakshi Taparua, Dr. Katia Tonkin, Dr. A. Robert Turner, Dr. Chris Venner, Dr. Peter Venner, Dr. John Walker); (TBCC: Dr. Gwyn Bebb, Dr. Vivien Bramwell, Dr. Cynthia Card, Dr. Tina Cheng, Dr. Scott Dowden, Dr. Jay Easaw, Dr. Sarah Glaze, Dr. Jan-Willem Henning, Dr. Neil Hagen, Dr. Desiree Hao, Dr. D. Heng, Dr. Vanessa Krause, Dr. Sasha Lupichuk, Dr. Jose Monzon, Dr. Don Morris, Dr. Alexander Paterson, Dr. Dean Ruether, Dr. Doug Stewart, Dr. Vincent Tam, Dr. Patricia Tang, Dr. Roger Tsang, Dr. Mike Vickers, Dr. Barb Walley, Dr. Marc Webster, Dr Victor Zepeda)

**GROUP 3 DRUG LIST**

Cancer Drugs in group 3 of the Schedule may be dispensed by a Cancer Pharmacy if

(a) the Cancer Drugs are part of a research or clinical drug trial approved by Alberta Health Services and the prescription is written by the principal investigator or co-investigator in charge of the trial, or

(b) the Cancer Drugs are approved for special access by Health Canada and a prescription is written by a Cancer Centre Medical Staff member designated as eligible by Albert Health Services to prescribe special access Cancer Drugs.

Reference: Ministerial Order #10/2009.

**ADMINISTRATION CLASSIFICATION**

CLASSIFICATION DESCRIPTION	DELIVERY SITE	STANDARDS
<p>Basic</p> <ul style="list-style-type: none"> <li>• Protocols including drugs (single agent or in combination) that can be administered with basic knowledge of chemotherapy.</li> <li>• Protocols including vesicants or drugs that are considered highly toxic where significant assessment and evaluation are required.</li> <li>• Protocols for basic clinical trials may be included on a case by case decision.</li> </ul>	<ul style="list-style-type: none"> <li>• Tertiary cancer centre</li> <li>• Associate cancer centre</li> <li>• Community cancer centre</li> </ul>	<ul style="list-style-type: none"> <li>• Medical, nursing and pharmacy staff shall have successfully completed the established ACB chemotherapy training programs.</li> <li>• Nurses will be certified in advanced chemotherapy and central venous catheters.</li> <li>• Pharmacy staff shall be certified in chemotherapy preparation and handling.</li> </ul>
<p>Advanced</p> <ul style="list-style-type: none"> <li>• Protocols including complex clinical trials, investigational drugs, new drugs, drugs requiring complex delivery devices (ex. electronic continuous infusion pumps)</li> <li>• Advanced chemotherapy in Community cancer centres, at this time, refers to medications only. It does not include advanced administration methods (i.e. electronic pumps) or complex clinical trials.</li> </ul>	<ul style="list-style-type: none"> <li>• Tertiary cancer centre</li> <li>• Associate cancer centre</li> <li>• Designated Community cancer centres: Barrhead, Bonnyville, Camrose, Canmore, Drayton Valley, Drumheller, Fort McMurray, High River, Hinton, Lloydminster</li> </ul>	<ul style="list-style-type: none"> <li>• As for Basic Classification.</li> <li>• Physicians supervising the complex clinical trials and investigational drug trials must have ready access to diagnostic procedures and data management.</li> <li>• Medical, nursing, and pharmacy staff shall have the knowledge and skill to manage complex delivery devices.</li> </ul>
<p>n/a</p>	<ul style="list-style-type: none"> <li>• Any health care setting</li> <li>• For oral and SC medications</li> <li>• Patient may self-administer</li> </ul>	<ul style="list-style-type: none"> <li>• No special training for health care professional required to administer.</li> </ul>

“Cancer Centre” means the following centres:

- Calgary Health Region Alberta Children’s Hospital
- Peter Lougheed Centre
- Stollery Children’s Hospital
- University of Alberta Hospital
- Tom Baker Cancer Centre, and the following associate and community centres:
  - Lethbridge Cancer Centre
  - Medicine Hat Cancer Centre
  - Drumheller Community Cancer Centre
  - High River Community Cancer Centre
  - Bow Valley Community Cancer Centre
- Cross Cancer Institute, and the following associate and community centres:
  - Central Alberta Cancer Centre (Red Deer)
  - Grande Prairie Cancer Centre
  - Barrhead Community Cancer Centre
  - Bonnyville Community Cancer Centre
  - Camrose Community Cancer Centre
  - Fort McMurray Community Cancer Centre
  - Hinton Community Cancer Centre
  - Peace River Community Cancer Centre
  - Lloydminster Community Cancer Centre
  - Drayton Valley Community Cancer Centre

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
ABIRATERONE	2	oral	<p><b>Prostate Cancer</b></p> <ul style="list-style-type: none"> <li>• For asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer (mCRPC) patients after failure of androgen deprivation therapy (ADT) and who have not received prior chemotherapy.</li> <li>• For treatment of metastatic, castration-resistant prostate cancer, who have previously received docetaxel therapy or if patients are unable to tolerate ongoing enzalutamide in this post docetaxel setting. Not to be used after progression on enzalutamide. Not to be used after progression on Abiraterone in the pre-docetaxel setting</li> </ul> <p>• Prescribing limited to written authorization by named physicians:</p> <p><b>CCI</b> Dr. Naveen Basappa, Dr. Scott North, Dr. Peter Venner</p> <p><b>TBCC</b> Dr. Tina Cheng, Dr. D. Heng, Dr. Dean Ruether, Dr. Vincent Tam, Dr. Mike Vickers</p> <p><b>Grande Prairie</b> Dr. Marie Moreau, Dr. Claudia Strehlke</p> <p><b>Lethbridge</b> Dr. Malcolm Brigden, Dr. Faraj El-Gehani</p> <p><b>Medicine Hat</b> Dr. Marc Trudeau</p> <p><b>Red Deer</b> Dr. Naveen Basappa, Dr. Neil Graham, Dr. Callisto Tarukandirwa, Dr. John Walker</p> <p>As recommended by the genitourinary tumour program or outlined under group 2 drugs on first page.</p>	<p>May/14</p> <p>Feb/12</p> <p>Dec/13 May/14</p>	

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
ALEMTUZUMAB	2	injectable	<p><b>Hematology / Lymphoma</b></p> <ul style="list-style-type: none"> <li>• subcutaneous plus fludarabine for previously treated CLL</li> <li>• Prescribing limited to written authorization by named physicians:</li> </ul> <p><b>CCI</b>            Dr. N. Basappa, Dr. Sanraj Basi, Dr. Andrew Belch,            Dr. Lauren Bolster, Dr. Joseph Brandwein, Dr. Neil Chua,            Dr. Amelie Fontaine, Dr. Melaku Game,            Dr. Marlene Hamilton, Dr. Loree Larratt, Dr. Elena Liew,            Dr. Jeff Patterson, Dr. Anthea Peters, Dr. Bruce Ritchie,            Dr. Lalit Saini, Dr. Irwindeep Sandhu, Dr. Randeep Sangha,            Dr. Minakshi Taparia, Dr. A. Robert Turner, Dr. Chris Venner,            Dr. Cynthia Wu, Dr. Nancy Zhu</p> <p><b>TBCC</b>            Dr. Nizar Bahlis, Dr. Walter Blahey, Dr. Chris Brown,            Dr. Andrew Daly, Dr. P. Duggan, Dr. Michelle Geddes,            Dr. Dawn Goodyear, Dr. Jennifer Grossman,            Dr. Deirdre Jenkins, Dr. Johannes Lategan, Dr. Adrienne Lee,            Dr. Ernesta Paola Neri, Dr. Carolyn Owen, Dr. Natalia Rydz,            Dr. Mary Lynn Savoie, Dr. M. Shafey, Dr. Jiri Slaby,            Dr. Doug Stewart, Dr. J. Storek, Dr. Lesley Street,            Dr. J.F. Ted Thael, Dr. Karen Valentine, Dr. M. Wong,            Dr. J. Yau, Dr. Victor Zepeda</p> <p><b>Grande Prairie</b>            Dr. Marie Moreau, Dr. Claudia Strehlke</p> <p><b>Lethbridge</b>            Dr. Stanley Benke, Dr. Malcolm Brigden,            Dr. Faraj El-Gehani</p> <p><b>Medicine Hat</b>            Dr. Marc Trudeau</p> <p><b>Red Deer</b>            Dr. Neil Graham, Dr. Kathryn Rudolph,            Dr. Callisto Tarukandirwa</p> <p>As recommended by the hematology/lymphoma tumour program or outlined under group 2 drugs on first page.</p>	Apr/12	Basic - SC
ANAGRELIDE	1	capsules		Mar/98 Apr/09	n/a
ANASTROZOLE	1	tablets		Apr/03Nov/ 03May/06 Mar/13 June/13	n/a

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
ARSENIC TRIOXIDE	2	injectable	<p><b>Hematology / Lymphoma</b></p> <ul style="list-style-type: none"> <li>• For patients with APL with t(15:17) translocation and PLM/RAR-alpha gene expression.               <ul style="list-style-type: none"> <li>-First line treatment in combination with all-trans retinoic acid (ATRA) and chemotherapy for the induction of remission and/or consolidation in patients with low, intermediate and high risk acute promyelocytic leukemia (APL)</li> <li>-Second line treatment for induction of remission and consolidation in patients with APL who have relapsed after completion of first line therapy (including ATO based regimens) or who have disease refractory to non ATO based regimens</li> </ul> </li> <li>• Prescribing limited to written authorization by named physicians:</li> </ul> <p><b>CCI</b></p> <p>Dr. N. Basappa, Dr. Sanraj Basi, Dr. Andrew Belch, Dr. Lauren Bolster, Dr. Joseph Brandwein, Dr. Neil Chua, Dr. Amelie Fontaine, Dr. Melaku Game, Dr. Marlene Hamilton, Dr. Loree Larratt, Dr. Elena Liew, Dr. Jeff Patterson, Dr. Anthea Peters, Dr. Bruce Ritchie, Dr. Lalit Saini, Dr. Irwindeep Sandhu, Dr. Randeep Sangha, Dr. Minakshi Taparia, Dr. A. Robert Turner, Dr. Chris Venner, Dr. Cynthia Wu, Dr. Nancy Zhu</p> <p><b>TBCC</b></p> <p>Dr. Nizar Bahlis, Dr. Walter Blahey, Dr. Chris Brown, Dr. Andrew Daly, Dr. P. Duggan, Dr. Michelle Geddes, Dr. Dawn Goodyear, Dr. Jennifer Grossman, Dr. Deirdre Jenkins, Dr. Johannes Lategan, Dr. Adrienne Lee, Dr. Ernesta Paola Neri, Dr. Carolyn Owen, Dr. Natalia Rydz, Dr. Mary Lynn Savoie, Dr. M. Shafey, Dr. Jiri Slaby, Dr. Doug Stewart, Dr. J. Storek, Dr. Lesley Street, Dr. J.F. Ted Thael, Dr. Karen Valentine, Dr. M. Wong, Dr. J. Yau, Dr. Victor Zepeda</p> <p><b>Grande Prairie</b></p> <p>Dr. Marie Moreau, Dr. Claudia Strehlke</p> <p><b>Lethbridge</b></p> <p>Dr. Stanley Benke, Dr. Malcolm Brigden, Dr. Faraj El-Gehani</p> <p><b>Medicine Hat</b></p> <p>Dr. Marc Trudeau</p> <p><b>Red Deer</b></p> <p>Dr. Neil Graham, Dr. Kathryn Rudolph, Dr. Callisto Tarukandirwa</p> <p>As recommended by the hematology/lymphoma tumour program or outlined under group 2 drugs on first page</p>	May/14	advanced
ASPARAGINASE	1	injectable			Advanced

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
AXITINIB	2		<p><b>Renal</b></p> <ul style="list-style-type: none"> <li>As second-line treatment of patients with metastatic clear cell renal carcinoma who, based on the mutual assessment of the treating physician and the patient, are unable to tolerate ongoing use of an effective dose of everolimus or who have a contraindication to everolimus.</li> <li>Prescribing limited to written authorization by named physicians:</li> </ul> <p><b>CCI</b> Dr. Naveen Basappa, Dr. Scott North, Dr. Peter Venner</p> <p><b>TBCC</b> Dr. Tina Cheng, Dr. D. Heng, Dr. Dean Ruether, Dr. Vincent Tam, Dr. Mike Vickers</p> <p><b>Grande Prairie</b> Dr. Marie Moreau, Dr. Claudia Strehlke</p> <p><b>Lethbridge</b> Dr. Malcolm Brigden, Dr. Faraj El-Gehani</p> <p><b>Medicine Hat</b> Dr. Marc Trudeau</p> <p><b>Red Deer</b> Dr. Naveen Basappa, Dr. Neil Graham, Dr. Callisto Tarukandirwa, Dr. John Walker</p> <p>As recommended by the GU tumour program or outlined under group 2 drugs on first page.</p>	Mar/14	
AZACITIDINE	2	injectable		May/10 Jun/14	Basic
BCG	1	injectable		Jan/91Apr/09	Bladder instillation - basic

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
BENDAMUSTINE	2	injectable	<p><b>Hematology</b></p> <ul style="list-style-type: none"> <li>• as a single agent for the treatment of relapsed or refractory indolent NHL in patients who are refractory or intolerant to rituximab</li> <li>• In combination with rituximab as first-line therapy in patients with indolent CD20 positive NHL or mantle cell lymphoma with an ECOG performance status of equal or less than 2.</li> <li>• In combination with rituximab for relapsed/refractory patients with indolent NHL or mantle cell lymphoma.</li> <li>• For the first line treatment of patients with chronic lymphocytic leukemia (Binet stage B or C and WHO performance status ≤ 2) who are not medically fit to tolerate fludarabine based regimens</li> <li>• Prescribing limited to written authorization by named physicians:</li> </ul> <p><b>CCI</b>            Dr. N. Basappa, Dr. Sanraj Basi, Dr. Andrew Belch, Dr. Lauren Bolster, Dr. Joseph Brandwein, Dr. Neil Chua, Dr. Amelie Fontaine, Dr. Melaku Game, Dr. Marlene Hamilton, Dr. Loree Larratt, Dr. Elena Liew, Dr. Jeff Patterson, Dr. Anthea Peters, Dr. Bruce Ritchie, Dr. Lalit Saini, Dr. Irwindeep Sandhu, Dr. Randeep Sangha, Dr. Minakshi Taparia, Dr. A. Robert Turner, Dr. Chris Venner, Dr. Cynthia Wu, Dr. Nancy Zhu</p> <p><b>TBCC</b>            Dr. Nizar Bahlis, Dr. Walter Blahey, Dr. Chris Brown, Dr. Andrew Daly, Dr. P. Duggan, Dr. Michelle Geddes, Dr. Dawn Goodyear, Dr. Jennifer Grossman, Dr. Deirdre Jenkins, Dr. Johannes Lategan, Dr. Adrienne Lee, Dr. Ernesta Paola Neri, Dr. Carolyn Owen, Dr. Natalia Rydz, Dr. Mary Lynn Savoie, Dr. M. Shafey, Dr. Jiri Slaby, Dr. Doug Stewart, Dr. J. Storek, Dr. Lesley Street, Dr. J.F. Ted Thael, Dr. Karen Valentine, Dr. M. Wong, Dr. J. Yau, Dr. Victor Zepeda</p> <p><b>Grande Prairie</b>            Dr. Marie Moreau, Dr. Claudia Strehlke</p> <p><b>Lethbridge</b>            Dr. Stanley Benke, Dr. Malcolm Brigden, Dr. Faraj El-Gehani</p> <p><b>Medicine Hat</b>            Dr. Marc Trudeau</p> <p><b>Red Deer</b>            Dr. Neil Graham, Dr. Kathryn Rudolph, Dr. Callisto Tarukandirwa</p> <p>As recommended by the hematology/lymphoma tumour program or outlined under group 2 drugs on first page.</p>	<p>Mar/14</p> <p>Mar/13</p> <p>July/13</p>	Basic

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
BEVACIZUMAB	2	Injectable	<p><b>Colorectal</b></p> <ul style="list-style-type: none"> <li>In combination with chemotherapy with one line of chemotherapy for the treatment of advanced colorectal cancer (indicated for any line of therapy provided bevacizumab naïve)</li> <li>Prescribing limited to written authorization by named physicians:</li> </ul> <p><b>CCI</b>            Dr. Naveen Basappa, Dr. Charles Butts, Dr. Neil Chua, Dr. A.L.A. Fields, Dr. Amelie Fontaine, Dr. Maria Ho, Dr. Karen King, Dr. Sheryl Koski, Dr. Karen Mulder, Dr. Julie Price Hiller, Dr. Michael Sawyer, Dr. Andrew Scarfe, Dr. Jennifer Spratlin, Dr. John Walker            Dr. Clarence Wong</p> <p><b>TBCC</b>            Dr. Gwyn Bebb, Dr. Walter Blahey, Dr. Tina Cheng, Dr. Scot Dowden, Dr. Jay Easaw, , Dr. Vanessa Krause, Dr. Sasha Lupichuk, Dr. Jose Monzon, Dr. Don Morris, Dr. Sandy Paterson, Dr. Dean Ruether, Dr. Doug Stewart, Dr. Vincent Tam, Dr. P. Tang, Dr. Ted Thael, Dr. Mike Vickers, Dr. Barb Walley</p> <p><b>Lethbridge</b>            Dr. Malcolm Brigden, Dr. Faraj El-Gehani</p> <p><b>Grande Prairie</b>            Dr. Marie Moreau, Dr. Claudia Strehlke</p> <p><b>Medicine Hat</b>            Dr. Marc Trudeau</p> <p><b>Red Deer</b>            Dr. Naveen Basappa, Dr. Neil Graham, Dr. Callisto Tarukandirwa, Dr. John Walker</p> <p>As recommended by the GI tumour program or outlined under group 2 drugs on first page</p>	Apr/09  Mar/13	Basic
BICALUTAMIDE	1	tablets		May/97 Apr/09	n/a
BLEOMYCIN	1	injectable			sc test dose, IV push, inf - basic
	1	pump			electronic continuous infusion pump - advanced



Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
BORTEZOMIB	2	injectable IV or SC at 1 mg/mL	<p><b>Hematology / Lymphoma</b></p> <ul style="list-style-type: none"> <li>• Relapsed Multiple Myeloma</li> <li>• in the first line treatment of previously untreated Multiple Myeloma who are not candidates for autologous stem cell transplantation (HDT-ASCT)</li> <li>• monotherapy or combination treatment for relapsed or refractory mantle cell lymphoma</li> <li>• As a component of induction therapy pre-autologous stem cell transplantation (ASCT) for newly diagnosed patients with multiple myeloma who are eligible for ASCT</li> <li>• Post autologous stem cell transplantation (ASCT) for 4 cycles of consolidation in those patients who obtained only partial response or stable disease and for maintenance therapy for two years in those patients who have the del17p</li> <li>• Prescribing limited to written authorization by named physicians:</li> </ul> <p><b>CCI</b>            Dr. N. Basappa, Dr. Sanraj Basi, Dr. Andrew Belch, Dr. Lauren Bolster, Dr. Joseph Brandwein, Dr. Neil Chua, Dr. Amelie Fontaine, Dr. Melaku Game, Dr. Marlene Hamilton, Dr. Loree Larratt, Dr. Elena Liew, Dr. Jeff Patterson, Dr. Anthea Peters, Dr. Bruce Ritchie, Dr. Lalit Saini, Dr. Irwindeep Sandhu, Dr. Randeep Sangha, Dr. Minakshi Taparia, Dr. A. Robert Turner, Dr. Chris Venner, Dr. Cynthia Wu, Dr. Nancy Zhu</p> <p><b>TBCC</b>            Dr. Nizar Bahlis, Dr. Walter Blahey, Dr. Chris Brown, Dr. Andrew Daly, Dr. P. Duggan, Dr. Michelle Geddes, Dr. Dawn Goodyear, Dr. Jennifer Grossman, Dr. Deirdre Jenkins, Dr. Johannes Lategan, Dr. Adrienne Lee, Dr. Ernesta Paola Neri, Dr. Carolyn Owen, Dr. Natalia Rydz, Dr. Mary Lynn Savoie, Dr. M. Shafey, Dr. Jiri Slaby, Dr. Doug Stewart, Dr. J. Storek, Dr. Lesley Street, Dr. J.F. Ted Thaell, Dr. Karen Valentine, Dr. M. Wong, Dr. J. Yau, Dr. Victor Zepeda</p> <p><b>Grande Prairie</b>            Dr. Marie Moreau, Dr. Claudia Strehlke</p> <p><b>Lethbridge</b>            Dr. Stanley Benke, Dr. Malcolm Brigden, Dr. Faraj El-Gehani</p> <p><b>Medicine Hat</b>            Dr. Marc Trudeau</p> <p><b>Red Deer</b>            Dr. Neil Graham, Dr. Kathryn Rudolph, Dr. Callisto Tarukandirwa</p> <p>As recommended by the hematology/lymphoma tumour program or outlined under group 2 drugs on first page.</p>	<p>Aug/06            May/08            July/11</p> <p>Oct/12</p> <p>July/13</p> <p>July/13</p>	<p>Basic IV or SC 1 mg/mL concentration</p>

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
BRENTUXIMAB	2	injectable	<p><b><u>Hematology – Hodgkin’s Lymphoma</u></b></p> <ul style="list-style-type: none"> <li>For patients with Hodgkin’s lymphoma who have relapsed disease following autologous stem cell transplant (ASCT) and who have an ECOG performance status of 0 or 1. For patient who weigh more than 100 kg doses are based on a weight of 100 kg.</li> </ul> <p><b><u>Hematology – Systemic Anaplastic Large Cell Lymphoma</u></b></p> <ul style="list-style-type: none"> <li>As monotherapy in patients with systemic anaplastic large cell lymphoma who have failed at least one prior multi-agent therapy and who have an ECOG performance status of 0 or 1.</li> <li>Prescribing limited to written authorization by named physicians:</li> </ul> <p><b>CCI</b>  Dr. N. Basappa, Dr. Sanraj Basi, Dr. Andrew Belch, Dr. Lauren Bolster, Dr. Joseph Brandwein, Dr. Neil Chua, Dr. Amelie Fontaine, Dr. Melaku Game, Dr. Marlene Hamilton, Dr. Loree Larratt, Dr. Elena Liew, Dr. Jeff Patterson, Dr. Anthea Peters, Dr. Bruce Ritchie, Dr. Lalit Saini, Dr. Irwindeep Sandhu, Dr. Randeep Sangha, Dr. Minakshi Taparia, Dr. A. Robert Turner, Dr. Chris Venner, Dr. Cynthia Wu, Dr. Nancy Zhu</p> <p><b>TBCC</b>  Dr. Nizar Bahlis, Dr. Walter Blahey, Dr. Chris Brown, Dr. Andrew Daly, Dr. P. Duggan, Dr Michelle Geddes, Dr. Dawn Goodyear, Dr. Jennifer Grossman, Dr. Deirdre Jenkins, Dr. Johannes Lategan, Dr. Adrienne Lee, Dr. Ernesta Paola Neri, Dr. Carolyn Owen, Dr. Natalia Rydz, Dr. Mary Lynn Savoie, Dr. M. Shafey, Dr. Jiri Slaby, Dr. Doug Stewart, Dr. J. Storek, Dr. Lesley Street, Dr. J.F. Ted Thael, Dr. Karen Valentine, Dr. M. Wong, Dr. J. Yau, Dr. Victor Zepeda</p> <p><b>Grande Prairie</b>  Dr. Marie Moreau, Dr. Claudia Strehlke</p> <p><b>Lethbridge</b>  Dr. Stanley Benke, Dr. Malcolm Brigden, Dr. Faraj El-Gehani</p> <p><b>Medicine Hat</b>  Dr. Marc Trudeau</p> <p><b>Red Deer</b>  Dr. Neil Graham, Dr. Kathryn Rudolph, Dr. Callisto Tarukandirwa</p> <p>As recommended by the hematology/lymphoma tumour program or outlined under group 2 drugs on first page.</p>	May/14	advanced

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
BUSERELIN	1	injectable	<p><b>Prostate Cancer</b></p> <ul style="list-style-type: none"> <li>Restricted to: <ul style="list-style-type: none"> <li>Stage II (T2a-T2c): Neoadjuvant use pre RT (2 months pre and during RT).</li> <li>Neoadjuvant use pre radical prostatectomy (4 months pre).</li> <li>Stage III (T3a-T4b): Neoadjuvant use pre RT (2 months pre and during RT).</li> <li>Adjuvant use (3 years post RT).</li> <li>Stage IV (N1-N3) (M1-M1c): As monotherapy in medical castration.</li> <li>In total androgen blockade (medical castration and nonsteroidal antiandrogen).</li> </ul> </li> <li>Guidelines for LHRH use in the above stated stages include: <ul style="list-style-type: none"> <li>LHRH agonists are indicated for use in patients at risk of thromboembolic disease, strokes (CVA), myocardial infarction and also for consideration in patients with dyslipidemia, hypertension, diabetes mellitus or where a patient is considered intolerant to cyproterone acetate or megestrol acetate.</li> </ul> </li> </ul>	Jan/98	n/a
BUSULFAN	1	tablets			n/a
CABAZITAXEL	2	injectable	<p><b>Prostate Cancer</b></p> <ul style="list-style-type: none"> <li>Cabazitaxel plus prednisone for patients with castration resistant metastatic prostate cancer previously treated with a docetaxel containing regimen</li> <li>Prescribing limited to written authorization by named physicians:</li> </ul> <p><b>CCI</b> Dr. Naveen Basappa, Dr. Scott North, Dr. Peter Venner</p> <p><b>TBCC</b> Dr. Tina Cheng, Dr. D. Heng, Dr. Dean Ruether, Dr. Vincent Tam, Dr. Mike Vickers</p> <p><b>Grande Prairie</b> Dr. Marie Moreau, Dr. Claudia Strehlke</p> <p><b>Lethbridge</b> Dr. Malcolm Brigden, Dr. Faraj El-Gehani</p> <p><b>Medicine Hat</b> Dr. Marc Trudeau</p> <p><b>Red Deer</b> Dr. Naveen Basappa, Dr. Neil Graham, Dr. Callisto Tarukandirwa, Dr. John Walker <li>As recommended by the genitourinary tumour program or outlined under group 2 drugs on first page.</li> </p>	Aug/12 May/14	Advanced
CAPECITABINE	2	oral		Dec/98 Jul/02 Oct/03 Jan/04 Jun/14	n/a

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
CARBOPLATIN	1	injectable		May/85	IV inf. - basic
CARMUSTINE	1	injectable, topical			IV inf. - basic
CETUXIMAB	2	injectable	<p><b>Head and Neck Cancer</b></p> <ul style="list-style-type: none"> <li>• Locally / regionally advanced head and neck squamous cell carcinoma</li> <li>• Patient has locally or regionally advanced squamous cell carcinoma of the head and neck without distant metastases, and</li> <li>• have Karnofsky Performance score <math>\geq</math> 90, and</li> <li>• cetuximab is used in combination with curative radical radiotherapy, and</li> <li>• recommended dosage is: Initially 400 mg/m<sup>2</sup>, then 250 mg/m<sup>2</sup> weekly for six to seven weeks.</li> <li>• Prescribing limited to written authorization by named physicians:</li> </ul> <p><b>CCI</b> Dr. Q. Chu, Dr. N. Chua, Dr. S. Koski, Dr. J. Mackey</p> <p><b>TBCC</b> Dr. D. Hao, Dr. M. Webster</p> <p>As recommended by the Head and Neck tumour group or outlined under group 2 drugs on first page.</p>	Oct/09  Oct/12	Advanced
CHLORAMBUCIL	1	tablets			n/a
CISPLATIN	1	injectable		Mar/90 May/06	IV inf. – basic Intraperitoneal - advanced
CLADRIBINE	1	injectable subcutaneous		Mar/96 Apr/09	IV inf., sc - basic Electronic continuous infusion pump - Advanced

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
CRIZOTINIB	2	oral	<p><b>Lung Cancer</b></p> <ul style="list-style-type: none"> <li>• as a second line monotherapy for use in patients with anaplastic lymphoma kinase (ALK)-positive advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) in patients who have prior first line therapy.</li> <li>• Prescribing limited to written authorization by named physicians:</li> </ul> <p><b>CCI</b> Dr. Dick Au, Dr. Naveen Basappa, Dr. Charles Butts, Dr. Quincy Chu, Dr. Anil Joy, Dr. Randeep Sangha, Dr. Michael Sawyer, Dr. Michael Smylie</p> <p><b>TBCC</b> Dr. Gwyn Bebb, Dr. Cynthia Card, Dr. Desiree Hao, Dr. Vanessa Krause, Dr. Don Morris, Dr. Dean Ruether, Dr. Vincent Tam, Dr. Roger Tsang Dr. Mike Vickers</p> <p><b>Grande Prairie</b> Dr. Marie Moreau, Dr. Claudia Strehlke</p> <p><b>Lethbridge</b> Dr. Malcolm Brigden, Dr. Faraj El-Gehani</p> <p><b>Medicine Hat</b> Dr. Marc Trudeau</p> <p><b>Red Deer</b> Dr. Naveen Basappa, Dr. Neil Graham, Dr. Callisto Tarukandirwa, Dr. John Walker</p> <p>As recommended by the lung tumour program or outlined under group 2 drugs on first page</p>	Oct/13	basic
CYCLOPHOSPHAMIDE	1	injectable, tablets			IV push, inf. - basic
CYPROTERONE	1	tablets		May/85	n/a
CYTARABINE	1	injectable		Mar/13	IV push, IT, inf., SC – basic
CYTARABINE, LIPOSOMAL	1	injectable		Mar/01 Apr/09	IT - advanced
DACARBAZINE	1	injectable			IV inf. - basic
DACTINOMYCIN	1	injectable			IV push - basic

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
DASATINIB	2	oral	<p><b>Hematology / Lymphoma</b></p> <ul style="list-style-type: none"> <li>• as first line treatment of Philadelphia Chromosome Positive CML in Chronic Phase (CML-CP)</li> <li>• For the treatment of adults with chronic, accelerated or blast phase chronic myeloid leukemia (CML) with resistance or intolerance to prior therapy including imatinib mesylate. Recommendations included the following: <ul style="list-style-type: none"> <li>• for adult patients with chronic phase CML with primary or acquired resistance to imatinib (600 mg/day) at doses of 100 mg per day or 70 mg two times daily</li> <li>• for adult patients with chronic phase CML who progress to accelerated phase on imatinib (600 mg/day). Dosing recommended: 140 mg per day</li> <li>• for adult patients with chronic phase CML who have blast crisis while on imatinib 600 mg/day. Dosing recommended: 140 mg per day</li> <li>• for adult patients with CML who have intolerance to imatinib or have experienced grade 3 or higher toxicities to imatinib</li> </ul> </li> <li>• For adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia whose disease is resistant to imatinib-containing chemotherapy (patient must have tried 600 mg/day) or have experienced grade 3 non-hematologic toxicity, or grade 4 hematologic toxicity persisting for more than 7 days to imatinib.</li> <li>• Prescribing limited to written authorization by named physicians:</li> </ul> <p><b>CCI</b>  Dr. N. Basappa, Dr. Sanraj Basi, Dr. Andrew Belch,  Dr. Lauren Bolster, Dr. Joseph Brandwein, Dr. Neil Chua, Dr. Amelie Fontaine, Dr. Melaku Game,  Dr. Marlene Hamilton, Dr. Loree Larratt, Dr. Elena Liew,  Dr. Jeff Patterson, Dr. Anthea Peters, Dr. Bruce Ritchie,  Dr. Lalit Saini, Dr. Irwindeep Sandhu,  Dr. Randeep Sangha, Dr. Minakshi Talaria,  Dr. A. Robert Turner, Dr. Chris Venner, Dr. Cynthia Wu,  Dr. Nancy Zhu</p> <p><b>TBCC</b>  Dr. Nizar Bahlis, Dr. Walter Blahey, Dr. Chris Brown,  Dr. Andrew Daly, Dr. P. Duggan, Dr. Michelle Geddes,  Dr. Dawn Goodyear, Dr. Jennifer Grossman,  Dr. Deirdre Jenkins, Dr. Johannes Lategan,  Dr. Adrienne Lee, Dr. Ernesta Paola Neri,  Dr. Carolyn Owen, Dr. Natalia Rydz, Dr. Mary Lynn Savoie,  Dr. M. Shafey, Dr. Jiri Slaby, Dr. Doug Stewart,  Dr. J. Storek, Dr. Lesley Street, Dr. J.F. Ted Thael,  Dr. Karen Valentine, Dr. M. Wong, Dr. J. Yau,  Dr. Victor Zepeda</p> <p><b>Grande Prairie</b>  Dr. Marie Moreau, Dr. Claudia Strehlke</p> <p><b>Lethbridge</b>  Dr. Stanley Benke, Dr. Malcolm Brigden,  Dr. Faraj El-Gehani</p> <p><b>Medicine Hat</b>  Dr. Marc Trudeau</p> <p><b>Red Deer</b>  Dr. Neil Graham, Dr. Kathryn Rudolph,  Dr. Callisto Tarukandirwa</p> <p>As recommended by the hematology/lymphoma tumour program or outlined under group 2 drugs on first page.</p>	Oct/12 Oct/09	n/a
DAUNORUBICIN	1	injectable			IV push, inf. - basic

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
DEXAMETHASONE	1	injectable, tablets	<ul style="list-style-type: none"> <li>• Antiemetic use NOT covered.</li> </ul>		n/a
DOCETAXEL	2	injectable		Mar/01 Apr/03 Jun/14	Advanced
DOXORUBICIN	1	injectable			IV push – basic Electronic continuous infusion pump - advanced
DOXORUBICIN LIPOSOMAL	2	injectable		Feb/99 Mar/01 Jul/02Feb/11 Jun/14	Advanced
ENZALUTAMIDE	2	oral	<p><b>Prostate Cancer</b></p> <ul style="list-style-type: none"> <li>• For the treatment of patients with metastatic castration resistant prostate cancer (mCRPC) who have previously received docetaxel, or if patients are unable to tolerate ongoing abiraterone in this post docetaxel setting. Not to be used after progression on abiraterone.</li> <li>• Prescribing limited to written authorization by named physicians:</li> </ul> <p><b>CCI</b> Dr. Naveen Basappa, Dr. Scott North, Dr. Peter Venner</p> <p><b>TBCC</b> Dr. Tina Cheng, Dr. D. Heng, Dr. Dean Ruether, Dr. Vincent Tam, Dr. Mike Vickers</p> <p><b>Grande Prairie</b> Dr. Marie Moreau, Dr. Claudia Strehlke</p> <p><b>Lethbridge</b> Dr. Malcolm Brigden, Dr. Faraj El-Gehani</p> <p><b>Medicine Hat</b> Dr. Marc Trudeau</p> <p><b>Red Deer</b> Dr. Naveen Basappa, Dr. Neil Graham, Dr. Callisto Tarukandirwa, Dr. John Walker</p> <p>As recommended by the GU tumour program or outlined under group 2 drugs on first page.</p>	Dec/13	
EPIRUBICIN	1	injectable		Mar/01 Jul/02 Sept/04 Jun/11	IV push - basic

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
ERIBULIN	2	injectable	<p><b>Breast Cancer</b></p> <ul style="list-style-type: none"> <li>for the treatment of patients with metastatic or incurable locally advanced breast cancer who have previous treatment with a taxane and an anthracycline, who have had at least two chemotherapy regimens for metastatic or locally recurrent disease and who have progressed after their last therapy. Patients must have good performance status (ECOG≤2).</li> <li>Prescribing limited to written authorization by named physicians:</li> </ul> <p><b>CCI</b>            Dr. Dick Au, Dr. Sanraj Basi, Dr. Maria Ho, Dr. Anil Joy, Dr. Karen King, Dr. John Mackey, Dr. Judith Meza-Junco, Dr. Julie Price Hiller, Dr. Andrew Scarfe, Dr. Michael Smylie, Dr. Katia Tonkin, Dr. John Walker</p> <p><b>TBCC</b>            Dr. Vivian Bramwell, Dr. Scot Dowden, Dr. D. Heng, Dr. Jan-Willem Henning, Dr. Vanessa Krause, Dr. Sasha Lupichuk, Dr. Alexander Paterson, Dr. Dean Ruether, Dr. Doug Stewart, Dr. Vincent Tam, Dr. Patricia Tang, Dr. Roger Tsang, Dr. Barb Walley, Dr. Marc Webster</p> <p><b>Grande Prairie</b>            Dr. Marie Moreau, Dr. Claudia Strehlke</p> <p><b>Lethbridge</b>            Dr. Malcolm Brigden, Dr. Faraj El-Gehani</p> <p><b>Medicine Hat</b>            Dr. Joshua Foley, Dr. Marc Trudeau</p> <p><b>Red Deer</b>            Dr. Naveen Basappa, Dr. Neil Graham, Dr. Callisto Tarukandirwa, Dr. John Walker</p> <p>As recommended by the breast tumour program or outlined under group 2 drugs on first page.</p>	Oct/13	basic
ERLOTINIB	2	tablets	<p><b>Lung</b></p> <ul style="list-style-type: none"> <li>For the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen and who have not received Gefitinib first line.</li> <li>Prescribing limited to written authorization by named physicians:</li> </ul> <p><b>CCI</b>            Dr. Dick Au, Dr. Naveen Basappa, Dr. Charles Butts, Dr. Quincy Chu, Dr. Anil Joy, Dr. Randeep Sangha, Dr. Michael Sawyer, Dr. Michael Smylie</p> <p><b>TBCC</b>            Dr. Gwyn Bebb, Dr. Cynthia Card, Dr. Desiree Hao, Dr. Vanessa Krause, Dr. Don Morris, Dr. Dean Ruether, Dr. Vincent Tam, Dr. Roger Tsang, Dr. Mike Vickers</p> <p><b>Grande Prairie</b>            Dr. Marie Moreau, Dr. Claudia Strehlke</p> <p><b>Lethbridge</b>            Dr. Malcolm Brigden, Dr. Faraj El-Gehani</p> <p><b>Medicine Hat</b>            Dr. Marc Trudeau</p> <p><b>Red Deer</b>            Dr. Naveen Basappa, Dr. Neil Graham, Dr. Callisto Tarukandirwa, Dr. John Walker</p> <p>As recommended by the lung tumour program or outlined under group 2 drugs on first page.</p>	Aug/06 July/13  Oct/11	n/a



Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
ERWINIA L-ASPARAGINASE	2	injectable		Feb/10 Jun/14	Advanced
ETOPOSIDE	1	injectable, capsules			IV inf. – basic
EVEROLIMUS	2	tablet	<p><b>Renal</b></p> <ul style="list-style-type: none"> <li>For the treatment of patients with metastatic renal cell carcinoma (mRCC) after failure of initial treatment with any VEGF- receptor TKIs (e.g. sunitinib, sorafenib, pazopanib).</li> <li>Prescribing limited to written authorization by named physicians:</li> </ul> <p><b>CCI</b> Dr. Naveen Basappa, Dr. Scott North, Dr. Peter Venner</p> <p><b>TBCC</b> Dr. Tina Cheng, Dr. D. Heng, Dr. Dean Ruether, Dr. Vincent Tam, Dr. Mike Vickers</p> <p><b>Grande Prairie</b> Dr. Marie Moreau, Dr. Claudia Strehlke</p> <p><b>Lethbridge</b> Dr. Malcolm Brigden, Dr. Faraj El-Gehani</p> <p><b>Medicine Hat</b> Dr. Marc Trudeau</p> <p><b>Red Deer</b> Dr. Naveen Basappa, Dr. Neil Graham, Dr. Callisto Tarukandirwa, Dr. John Walker</p> <p>As recommended by the GU tumour program or outlined under group 2 drugs on first page.</p>	Feb/11 Mar/14	n/a
			<p><b>pNET</b></p> <ul style="list-style-type: none"> <li>For the treatment of patients with well or moderately – differentiated neuro-endocrine tumors of pancreatic origins (pNETs) in patients with unresectable, locally advanced or metastatic disease who have not previously been treated with sunitinib (unless intolerant)</li> <li>Prescribing limited to written authorization by named physicians:</li> </ul> <p><b>CCI</b> Dr. N Basappa, Dr. C Butts, Dr. N Chua, Dr. M Ho, Dr. K King, Dr. S Koski, Dr. J Meza-Junco, Dr. K Mulder, Dr. J Price Hiller, Dr. M Sawyer, Dr. A Scarfe, Dr. J Spratlin, Dr. John Walker, Dr. C Wong</p> <p><b>TBCC</b> Dr. C Card, Dr. JD Ruether, Dr. S. Dowden</p> <p><b>Grande Prairie</b> Dr. M Moreau, Dr. C Strehlke</p> <p><b>Lethbridge</b> Dr. M Brigden, Dr. F El-Gehani</p> <p><b>Medicine Hat</b> Dr. M Trudeau</p> <p><b>Red Deer</b> Dr. Naveen Basappa, Dr. Neil Graham, Dr. Callisto Tarukandirwa, Dr. John Walker</p> <p><b>As recommended by the endocrine or gastrointestinal tumor program.</b></p>	Mar/13	

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
EVEROLIMUS	2	tablet	<p><b>Breast Cancer</b></p> <ul style="list-style-type: none"> <li>For the treatment of hormone-receptor positive, HER2 negative advanced breast cancer in post menopausal women (ECOG ≤ 2) after recurrence or progression following a non-steroidal aromatase inhibitor (NSAI), If the treating oncologist would consider using exemestane.</li> <li>Prescribing limited to written authorization by named physicians:</li> </ul> <p><b>CCI</b>                      Dr. Dick Au, Dr. Sanraj Basi, Dr. Maria Ho, Dr. Anil Joy, Dr. Karen King, Dr. John Mackey, Dr. Judith Meza-Junco, Dr. Julie Price Hiller, Dr. Andrew Scarfe, Dr. Michael Smylie, Dr. Katia Tonkin, Dr. John Walker</p> <p><b>TBCC</b>                      Dr. Vivian Bramwell, Dr. Scot Dowden, Dr. D. Heng, Dr. Jan-Willem Henning, Dr. Vanessa Krause, Dr. Sasha Lupichuk, Dr. Alexander Paterson, Dr. Dean Ruether, Dr. Doug Stewart, Dr. Vincent Tam, Dr. Patricia Tang, Dr. Roger Tsang, Dr. Barb Walley, Dr. Marc Webster</p> <p><b>Grande Prairie</b>                      Dr. Marie Moreau, Dr. Claudia Strehlke</p> <p><b>Lethbridge</b>                      Dr. Malcolm Brigden, Dr. Faraj El-Gehani</p> <p><b>Medicine Hat</b>                      Dr. Joshua Foley, Dr. Marc Trudeau</p> <p><b>Red Deer</b>                      Dr. Naveen Basappa, Dr. Neil Graham, Dr. Callisto Tarukandirwa, Dr. John Walker</p> As recommended by the breast tumour program or outlined under group 2 drugs on first page.	Dec/13	n/a
EXEMESTANE	1	oral		Mar/01 Jan/04 Apr/04 May/06 Mar/13 July/13	n/a
FLUDARABINE	1	injectable, tablets		Mar/96 Apr/09	IV inf. - basic
FLUOROURACIL	1	injectable, cream			IV push, inf. - basic
	1	pump	electronic continuous infusion pumps. Baxter (elastomeric) pumps.	Jan/02 Jan/02	Advanced Basic
FLUTAMIDE	1	tablets		May/85 Apr/09	n/a

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
GEFITINIB	2	tablets	<p><b>Lung</b></p> <ul style="list-style-type: none"> <li>• For the first line treatment of epidermal growth factor receptor (EGFR) sensitizing mutation positive non-small cell lung cancer (NSCLC)</li> <li>• Prescribing limited to written authorization by named physicians:</li> </ul> <p><b>CCI</b> Dr. Dick Au, Dr. Naveen Basappa, Dr. Charles Butts, Dr. Quincy Chu, Dr. Anil Joy, Dr. Randeep Sangha, Dr. Michael Sawyer, Dr. Michael Smylie</p> <p><b>TBCC</b> Dr. Gwyn Bebb, Dr. Cynthia Card, Dr. Desiree Hao, Dr. Vanessa Krause, Dr. Don Morris, Dr. Dean Ruether, Dr. Vincent Tam, Dr. Roger Tsang, Dr. Mike Vickers</p> <p><b>Grande Prairie</b> Dr. Marie Moreau, Dr. Claudia Strehlke</p> <p><b>Lethbridge</b> Dr. Malcolm Brigden, Dr. Faraj El-Gehani</p> <p><b>Medicine Hat</b> Dr. Marc Trudeau</p> <p><b>Red Deer</b> Dr. Naveen Basappa, Dr. Neil Graham, Dr. Callisto Tarukandirwa, Dr. John Walker</p> <p>As recommended by the lung tumour program or outlined under group 2 drugs on first page.</p>	Oct/11	n/a
GEMCITABINE	1	injectable		May/10 Jun/11	Basic IV and intravesical use (bladder instillation)
GOSERELIN	1	injectable	<p><b>Prostate Cancer</b></p> <ul style="list-style-type: none"> <li>• Restricted to: <ul style="list-style-type: none"> <li>• Stage II (T2a-T2c): Neoadjuvant use pre RT (2 months pre and during RT).</li> <li>• Neoadjuvant use pre radical prostatectomy (4 months pre).</li> <li>• Stage III (T3a-T4b): Neoadjuvant use pre RT (2 months pre and during RT).</li> <li>• Adjuvant use (3 years post RT).</li> <li>• Stage IV (N1-N3) (M1-M1c): As monotherapy in medical castration.</li> <li>• In total androgen blockade (medical castration and nonsteroidal antiandrogen).</li> </ul> </li> <li>• Guidelines for LHRH use in the above stated stages include: <ul style="list-style-type: none"> <li>• LHRH agonists are indicated for use in patients at risk of thromboembolic disease, strokes (CVA), myocardial infarction and also for consideration in patients with dyslipidemia, hypertension, diabetes mellitus or where a patient is considered intolerant to cyproterone acetate or megestrol acetate.</li> </ul> </li> </ul>	Jan/98	n/a

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
GOSERELIN	2	injectable	<p><b>Breast Cancer. Metastatic</b></p> <ul style="list-style-type: none"> <li>As first line treatment in pre- and peri- menopausal patients with metastatic breast cancer.</li> </ul> <p><b>Breast Cancer Adjuvant:</b></p> <ul style="list-style-type: none"> <li>Pending clinical trial confirmation, treatment with ovarian suppression along with GnRH agonists is not generally indicated in the adjuvant setting, however may be considered an adjuvant treatment option for pre-menopausal patients who have had hormone receptor positive breast cancer, and are eligible for adjuvant chemotherapy but either: a) decline chemotherapy, b) or where chemotherapy is contraindicated, or c) have a contraindication to adjuvant tamoxifen</li> <li>Prescribing limited to written authorization by named physicians:</li> </ul> <p><b>CCI</b>                      Dr. Dick Au, Dr. Sanraj Basi, Dr. Maria Ho, Dr. Anil Joy, Dr. Karen King, Dr. John Mackey, Dr. Judith Meza-Junco, Dr. Julie Price Hiller, Dr. Andrew Scarfe, Dr. Michael Smylie, Dr. Katia Tonkin, Dr. John Walker</p> <p><b>TBCC</b>                      Dr. Vivian Bramwell, Dr. Scot Dowden, Dr. D. Heng, Dr. Jan-Willem Henning, Dr. Vanessa Krause, Dr. Sasha Lupichuk, Dr. Alexander Paterson, Dr. Dean Ruether, Dr. Doug Stewart, Dr. Vincent Tam, Dr. Patricia Tang, Dr. Roger Tsang, Dr. Barb Walley, Dr. Marc Webster</p> <p><b>Grande Prairie</b>                      Dr. Marie Moreau, Dr. Claudia Strehlke</p> <p><b>Lethbridge</b>                      Dr. Malcolm Brigden, Dr. Faraj El-Gehani</p> <p><b>Medicine Hat</b>                      Dr. Joshua Foley, Dr. Marc Trudeau</p> <p><b>Red Deer</b>                      Dr. Naveen Basappa, Dr. Neil Graham, Dr. Callisto Tarukandirwa, Dr. John Walker</p> <p>As recommended by the breast tumour program or outlined under group 2 drugs on first page.</p>	Dec/98 Jul/02 Dec/10  Feb/05 Oct/12	n/a
HYDROCORTISONE SODIUM SUCCINATE	1	injectable	<ul style="list-style-type: none"> <li>Intrathecal use only.</li> </ul>		IT – basic
HYDROXYUREA	1	capsules			n/a
IDARUBICIN	1	injectable		Jul/98 Apr/09	
IFOSFAMIDE	1	injectable			IV inf. – basic

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
IMATINIB	2	tablets	<p><b>Musculoskeletal</b></p> <ul style="list-style-type: none"> <li>• for adjuvant treatment of patients who are at high risk of relapse following complete resection of KIT (CD117) positive GIST</li> <li>• For surgically unresectable or metastatic gastrointestinal stromal tumour (GIST).</li> <li>• Prescribing limited to written authorization by named physicians:</li> </ul> <p><b>CCI:</b> Dr. Naveen Basappa, Dr. Quincy Chu, Dr. Karen Mulder, Dr. S. Mckillop, Dr. A. Robert Turner</p> <p><b>TBCC:</b> Dr. Vivian Bramwell, Dr. Jan-Willem Henning, Dr. Don Morris, Dr. Vincent Tam, Dr. Mike Vickers</p> <p><b>Medicine Hat</b> Dr. Marc Trudeau</p> <p><b>Lethbridge</b> Dr. Malcolm Brigden, Dr. Faraj El-Gehani</p> <p><b>Red Deer</b> Dr. Naveen Basappa, Dr. Callisto Tarukandirwa, Dr. John Walker As recommended by the musculoskeletal tumour program or outlined under group 2 drugs on first page.</p>	Apr/03 Oct/12	n/a
			<p><b>Hematology / Lymphoma</b></p> <ul style="list-style-type: none"> <li>• Philadelphia-chromosome positive leukemia (including disease situations such as first chronic phase chronic myelogenous leukemia (CML), accelerated phase CML, blast crisis phase CML, acute lymphoblastic leukemia, or other leukemia's that have the characteristic t (9;22) trans location detected by cytogenetics, FISH analysis, or PCR-positive for bcr-abl oncogene)</li> <li>• Prescribing limited to written authorization by named physicians:</li> </ul> <p><b>CCI</b> Dr. N. Basappa, Dr. Sanraj Basi, Dr. Andrew Belch, Dr. Lauren Bolster, Dr. Joseph Brandwein, Dr. Neil Chua, Dr. Amelie Fontaine, Dr. Melaku Game, Dr. Marlene Hamilton, Dr. Loree Larratt, Dr. Elena Liew, Dr. Jeff Patterson, Dr. Anthea Peters, Dr. Bruce Ritchie, Dr. Lalit Saini, Dr. Irwindeep Sandhu, Dr. Randeep Sangha, Dr. Minakshi Talaria, Dr. A. Robert Turner, Dr. Chris Venner, Dr. Cynthia Wu, Dr. Nancy Zhu</p> <p><b>TBCC</b> Dr. Nizar Bahlis, Dr. Walter Blahey, Dr. Chris Brown, Dr. Andrew Daly, Dr. P. Duggan, Dr Michelle Geddes, Dr. Dawn Goodyear, Dr. Jennifer Grossman, Dr. Deirdre Jenkins, Dr. Johannes Lategan, Dr. Adrienne Lee, Dr. Ernesta Paola Neri, Dr. Carolyn Owen, Dr. Natalia Rydz, Dr. Mary Lynn Savoie, Dr. M. Shafey, Dr. Jiri Slaby, Dr. Doug Stewart, Dr. J. Storek, Dr. Lesley Street, Dr. J.F. Ted Thael, Dr. Karen Valentine, Dr. M. Wong, Dr. J. Yau, Dr. Victor Zepeda</p> <p><b>Grande Prairie</b> Dr. Marie Moreau, Dr. Claudia Strehlke</p> <p><b>Lethbridge</b> Dr. Stanley Benke, Dr. Malcolm Brigden, Dr. Faraj El-Gehani</p> <p><b>Medicine Hat</b> Dr. Marc Trudeau</p> <p><b>Red Deer</b> Dr. Neil Graham, Dr. Kathryn Rudolph, Dr. Callisto Tarukandirwa As recommended by the hematology/lymphoma tumour program or outlined under group 2 drugs on first page.</p>	Apr/03 Oct/03	n/a
INTERFERON alpha 2b	1	injectable		Jul/97 Apr/09	Basic

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
IPILIMUMAB	2	injectable	<p><b>Melanoma</b></p> <ul style="list-style-type: none"> <li>For the treatment of advanced melanoma (unresectable Stage III or Stage IV melanoma) in patients who have received prior systemic therapy</li> <li>Prescribing limited to written authorization by named physicians:</li> </ul> <p><b>CCI</b> Dr. Michael Smylie, Dr. John Walker</p> <p><b>TBCC</b> Dr. Tina Cheng, Dr. Jose Monzon</p> <p>As recommended by the cutaneous tumour program or outlined under group 2 drugs on first page</p>	<u>Oct/12</u>	Advanced
IRINOTECAN	1	injectable		Jan/00 Mar/98 Oct/03 Jul/06 Aug/09	IV inf. – basic
*Note: Loperamide supplied by industry with this agent's use.					
ISOTRETINOIN	1	capsules		Mar/99 Apr/09	n/a
LAPATINIB	2	tablets	<p><b>Breast Cancer – Metastatic/Advanced</b></p> <ul style="list-style-type: none"> <li>in combination with capecitabine for the treatment of patients with advanced/metastatic breast cancer whose tumours overexpress ErbB2 (HER-2) after prior taxane and trastuzumab exposure.</li> <li>Prescribing limited to written authorization by named physicians:</li> </ul> <p><b>CCI</b> Dr. Dick Au, Dr. Sanraj Basi, Dr. Maria Ho, Dr. Anil Joy, Dr. Karen King, Dr. John Mackey, Dr. Judith Meza-Junco, Dr. Julie Price Hiller, Dr. Andrew Scarfe, Dr. Michael Smylie, Dr. Katia Tonkin, Dr. John Walker</p> <p><b>TBCC</b> Dr. Vivian Bramwell, Dr. Scot Dowden, Dr. D. Heng, Dr. Jan-Willem Henning, Dr. Vanessa Krause, Dr. Sasha Lupichuk, Dr. Alexander Paterson, Dr. Dean Ruether, Dr. Doug Stewart, Dr. Vincent Tam, Dr. Patricia Tang, Dr. Roger Tsang, Dr. Barb Walley, Dr. Marc Webster</p> <p><b>Grande Prairie</b> Dr. Marie Moreau, Dr. Claudia Strehlke</p> <p><b>Lethbridge</b> Dr. Malcolm Brigden, Dr. Faraj El-Gehani</p> <p><b>Medicine Hat</b> Dr. Joshua Foley, Dr. Marc Trudeau</p> <p><b>Red Deer</b> Dr. Naveen Basappa, Dr. Neil Graham, Dr. Callisto Tarukandirwa, Dr. John Walker</p> <ul style="list-style-type: none"> <li>As recommended by the breast tumour program or outlined under group 2 drugs on first page.</li> </ul>	Feb/11  Aug/12	n/a

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
LENALIDOMIDE	2	capsules	<p><b>MDS</b> – for the treatment of anemia due to myelodysplastic syndrome with a deletion of 5q cytogenetic abnormality</p> <p><b>Multiple Myeloma</b></p> <ul style="list-style-type: none"> <li>Multiple myeloma after at least one prior therapy</li> <li>Prescribing limited to named physicians WHO ARE REGISTERED IN EPPP PROGRAM WITH A SPECIFIC PRESCRIBER ID NUMBER:</li> </ul> <p><b>CCI</b> Dr. Andrew Belch, Dr. Neil Chua, Dr. Marlene Hamilton, Dr. Loree Larratt, Dr. Irwindeep Sandhu, Dr. A. Robert Turner, Dr. Chris Venner, Dr. Nancy Zhu</p> <p><b>TBCC</b> Dr. Nizar Bahlis, Dr. Walter Blahey, Dr. Chris Brown, Dr. Andrew Daly, Dr. P. Duggan, Dr. Michelle Geddes, Dr. Dawn Goodyear, Dr. Jennifer Grossman, Dr. Deirdre Jenkins, Dr. Johannes Lategan, Dr. Adrienne Lee, Dr. Ernesta Paola Neri, Dr. Carolyn Owen, Dr. Natalia Rydz, Dr. Mary Lynn Savoie, Dr. M. Shafey, Dr. Jiri Slaby, Dr. Doug Stewart, Dr. J. Storek, Dr. Lesley Street, Dr. J.F. Ted Thaell, Dr. Karen Valentine, Dr. M. Wong, Dr. J. Yau, Dr. Victor Zepeda</p> <p><b>Grande Prairie</b> Dr. Garth Campbell, Dr. Jacolette Hattingh, Dr. Marie A. Moreau, Dr. Claudia Strehlke</p> <p><b>Lethbridge</b> Dr. Stanley Benke, Dr. Malcolm Brigden, Dr. Faraj El-Gehani</p> <p><b>Medicine Hat</b> Dr. Marc Trudeau</p> <p><b>Red Deer</b> Dr. Neil Graham, Dr. Callisto Tarukandirwa</p>	Aug/09  Oct/09	n/a
LETROZOLE	1	tablets		Oct/98 Jul/02 Apr/03 Feb/06 Oct/07 Mar/13 July/13	n/a
LEUCOVORIN CALCIUM	1	injectable, tablets		Jul/92 Apr/09	n/a
LEUPROLIDE	1	injectable	<p><b>Prostate Cancer</b></p> <ul style="list-style-type: none"> <li>Restricted to: <ul style="list-style-type: none"> <li>Stage II (T2a-T2c): Neoadjuvant use pre RT (2 months pre and during RT).</li> <li>Neoadjuvant use pre radical prostatectomy (4 months pre).</li> <li>Stage III (T3a-T4b): Neoadjuvant use pre RT (2 months pre and during RT).</li> <li>Adjuvant use (3 years post RT).</li> <li>Stage IV (N1-N3) (M1-M1c): As monotherapy in medical castration.</li> <li>In total androgen blockade (medical castration and nonsteroidal antiandrogen).</li> </ul> </li> <li>Guidelines for LHRH use in the above stated stages include: <ul style="list-style-type: none"> <li>LHRH agonists are indicated for use in patients at risk of thromboembolic disease, strokes (CVA), myocardial infarction and also for consideration in patients with dyslipidemia, hypertension, diabetes mellitus or where a patient is considered intolerant to cyproterone acetate or megestrol acetate.</li> </ul> </li> </ul>	Jan/98	n/a

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
LOMUSTINE	1	capsules			n/a
MEDROXYPROGESTERONE ACETATE	1	tablets			n/a
MEGESTROL ACETATE	1	tablets			n/a
MELPHALAN	1	tablets			n/a
MERCAPTOPYRINE	1	tablets			n/a
MESNA	1	injectable			n/a
METHOTREXATE	1	injectable, tablets			IM, IV push, IT, IV inf. – basic
METHYLPREDNISOLONE	1	Injectable		Jun/14	basic
MITOMYCIN	1	injectable	• 3rd line for bladder cancer indication		Bladder instillation, IV push – basic
MITOTANE	1	oral		May/08 Sep/10	n/a
MITOXANTRONE	1	injectable		May/85	IV push, inf. – basic
(nab)-PACLITAXEL	2	injectable	<p><b>Breast Cancer - Metastatic</b></p> <ul style="list-style-type: none"> <li>patients who have had severe acute infusion reactions with paclitaxel or docetaxel, considered by the treating physician to be due to the vehicle of the taxanes (cremophor and polysorbate80); or patients who have experienced severe toxicity* from previous administration of other taxanes. *severe toxicity could be due to the pre-medications for the administration of the taxane or due to the taxane itself.</li> <li>Prescribing limited to written authorization by named physicians:</li> </ul> <p><b>CCI</b> Dr. Dick Au, Dr. Sanraj Basi, Dr. Maria Ho, Dr. Anil Joy, Dr. Karen King, Dr. John Mackey, Dr. Judith Meza-Junco, Dr. Julie Price Hiller, Dr. Andrew Scarfe, Dr. Michael Smylie, Dr. Katia Tonkin, Dr. John Walker</p> <p><b>TBCC</b> Dr. Vivian Bramwell, Dr. Scot Dowden, Dr. D. Heng, Dr. Jan-Willem Henning, Dr. Vanessa Krause, Dr. Sasha Lupichuk, Dr. Alexander Paterson, Dr. Dean Ruether, Dr. Doug Stewart, Dr. Vincent Tam, Dr. Patricia Tang, Dr. Roger Tsang, Dr. Barb Walley, Dr. Marc Webster</p> <p><b>Grande Prairie</b> Dr. Marie Moreau, Dr. Claudia Strehlke</p> <p><b>Lethbridge</b> Dr. Malcolm Brigden, Dr. Faraj El-Gehani</p> <p><b>Medicine Hat</b> Dr. Joshua Foley, Dr. Marc Trudeau</p> <p><b>Red Deer</b> Dr. Naveen Basappa, Dr. Neil Graham, Dr. Callisto Tarukandirwa, Dr. John Walker</p> <p>As recommended by the breast tumour program or outlined under group 2 drugs on first page.</p>	Jan/08 Apr/09	IV-advanced



Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
NILETINIB	2	capsule	<p><b>Hematology</b></p> <ul style="list-style-type: none"> <li>• as first line treatment of Philadelphia Chromosome Positive CML in Chronic Phase (CML-CP)</li> <li>• <b>as second line alternative for Imatinib resistant or intolerant, or Dasatinib intolerant CML patients.</b></li> <li>• Prescribing limited to written authorization by named physicians:</li> </ul> <p><b>CCI</b>            Dr. N. Basappa, Dr. Sanraj Basi, Dr. Andrew Belch, Dr. Lauren Bolster, Dr. Joseph Brandwein, Dr. Neil Chua, Dr. Amelie Fontaine, Dr. Melaku Game, Dr. Marlene Hamilton, Dr. Loree Larratt, Dr. Elena Liew, Dr. Jeff Patterson, Dr. Anthea Peters, Dr. Bruce Ritchie, Dr. Lalit Saini, Dr. Irwindeep Sandhu, Dr. Randeep Sangha, Dr. Minakshi Taparia, Dr. A. Robert Turner, Dr. Chris Venner, Dr. Cynthia Wu, Dr. Nancy Zhu</p> <p><b>TBCC</b>            Dr. Nizar Bahlis, Dr. Walter Blahey, Dr. Chris Brown, Dr. Andrew Daly, Dr. P. Duggan, Dr. Michelle Geddes, Dr. Dawn Goodyear, Dr. Jennifer Grossman, Dr. Deirdre Jenkins, Dr. Johannes Lategan, Dr. Adrienne Lee, Dr. Ernesta Paola Neri, Dr. Carolyn Owen, Dr. Natalia Rydz, Dr. Mary Lynn Savoie, Dr. M. Shafey, Dr. Jiri Slaby, Dr. Doug Stewart, Dr. J. Storek, Dr. Lesley Street, Dr. J.F. Ted Thael, Dr. Karen Valentine, Dr. M. Wong, Dr. J. Yau, Dr. Victor Zepeda</p> <p><b>Grande Prairie</b>            Dr. Marie Moreau, Dr. Claudia Strehlke</p> <p><b>Lethbridge</b>            Dr. Stanley Benke, Dr. Malcolm Brigden, Dr. Faraj El-Gehani</p> <p><b>Medicine Hat</b>            Dr. Marc Trudeau</p> <p><b>Red Deer</b>            Dr. Neil Graham, Dr. Kathryn Rudolph, Dr. Callisto Tarukandirwa</p> <p>As recommended by the hematology/lymphoma tumour program or outlined under group 2 drugs on first page.</p>	Dec/10 Oct/12	n/a
NILUTAMIDE	1	tablets		Jan/93 Apr/09	n/a

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
OXALIPLATIN	2	injectable	<p><b>Oxaliplatin – Colorectal Cancer Metastatic</b></p> <ul style="list-style-type: none"> <li>• Oxaliplatin in conjunction with a fluoropyrimidine (eg 5-Fluorouracil, capecitabine) in the treatment of advanced or metastatic colorectal cancer.</li> </ul> <p><b>Oxaliplatin – Colorectal Cancer Adjuvant</b></p> <ul style="list-style-type: none"> <li>• Oxaliplatin adjuvant therapy for Stage III and high risk Stage II Colorectal Cancer</li> </ul> <p><b>Oxaliplatin – Pancreatic Cancer</b></p> <ul style="list-style-type: none"> <li>• First line in patients with metastatic adenocarcinoma of the pancreas (as a component of FOLFIRINOX)</li> <li>• Prescribing limited to written authorization by named physicians</li> </ul> <p><b>CCI</b>            Dr. Naveen Basappa, Dr. Charles Butts, Dr. Neil Chua, Dr. A.L.A. Fields, Dr. Amelie Fontaine, Dr. Maria Ho, Dr. Karen King, Dr. Sheryl Koski, Dr. Karen Mulder, Dr. Julie Price Hiller, Dr. Michael Sawyer, Dr. Andrew Scarfe, Dr. Jennifer Spratlin, Dr. John Walker            Dr. Clarence Wong</p> <p><b>TBCC</b>            Dr. Gwyn Bebb, Dr. Walter Blahey, Dr. Tina Cheng, Dr. Scot Dowden, Dr. Jay Easaw, , Dr. Vanessa Krause, Dr. Sasha Lupichuk, Dr. Jose Monzon, Dr. Don Morris, Dr. Sandy Paterson, Dr. Dean Ruether, Dr. Doug Stewart, Dr. Vincent Tam, Dr. P. Tang, Dr. Ted Thaeil, Dr. Mike Vickers, Dr. Barb Walley</p> <p><b>Lethbridge</b>            Dr. Malcolm Brigden, Dr. Faraj El-Gehani</p> <p><b>Grande Prairie</b>            Dr. Marie Moreau, Dr. Claudia Strehlke</p> <p><b>Medicine Hat</b>            Dr. Marc Trudeau</p> <p><b>Red Deer</b>            Dr. Naveen Basappa, Dr. Neil Graham, Dr. Callisto Tarukandirwa, Dr. John Walker            As recommended by the GI tumour program or outlined under group 2 drugs on first page</p>	Mar 07 Oct/07 Apr/09 <hr/> Mar/07 May/10 <hr/> Oct/11	IV-basic
PACLITAXEL	1	injectable		Dec/98 Apr/09	IV, Intraperitoneal – advanced
PANITUMUMAB	2	injectable		Oct/09 Jun/14	Basic

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
PAZOPANIB	2	oral	<p><b>Renal</b></p> <ul style="list-style-type: none"> <li>As an option in the first line treatment of advanced or metastatic clear cell renal cell carcinoma for patients with good performance status or if patients are unable to tolerate ongoing sunitinib. Not to be used after progression on sunitinib.</li> <li>Prescribing limited to written authorization by named physicians:</li> </ul> <p><b>CCI</b> Dr. Naveen Basappa, Dr. Scott North, Dr. Peter Venner</p> <p><b>TBCC</b> Dr. Tina Cheng, Dr. D. Heng, Dr. Dean Ruether, Dr. Vincent Tam, Dr. Mike Vickers</p> <p><b>Grande Prairie</b> Dr. Marie Moreau, Dr. Claudia Strehlke</p> <p><b>Lethbridge</b> Dr. Malcolm Brigden, Dr. Faraj El-Gehani</p> <p><b>Medicine Hat</b> Dr. Marc Trudeau</p> <p><b>Red Deer</b> Dr. Naveen Basappa, Dr. Neil Graham, Dr. Callisto Tarukandirwa, Dr. John Walker</p> <p>As recommended by the GU tumour program or outlined under group 2 drugs on first page.</p>	Mar/14 Feb/12	
PEMETREXED	2	injectable	<p><b>Lung and Gastrointestinal</b></p> <ul style="list-style-type: none"> <li>Pemetrexed (in combination with cisplatin) for use in patients with malignant mesothelioma</li> <li>Pemetrexed first line with Platinum followed by maintenance pemetrexed for the treatment of advanced non-small cell lung cancer with non-squamous histology.</li> <li>maintenance pemetrexed for the treatment of patients with advanced non-small cell lung cancer (NSCLC) of non-squamous histology following four cycles of palliative platinum-doublet chemotherapy</li> <li>for second line treatment of patients with non-small cell lung cancer (may be used as third line systemic therapy if prior treatment with an EGFR TKI or ALK inhibitor)</li> <li>Prescribing limited to written authorization by named physicians:</li> </ul> <p><b>CCI</b> Dr. Naveen Basappa, Dr. Charles Butts, Dr. Neil Chua, Dr. A.L.A. Fields, Dr. Amelie Fontaine, Dr. Maria Ho, Dr. Karen King, Dr. Sheryl Koski, Dr. Karen Mulder, Dr. Julie Price Hiller, Dr. Michael Sawyer, Dr. Andrew Scarfe, Dr. Jennifer Spratlin, Dr. John Walker Dr. Clarence Wong</p> <p><b>TBCC</b> Dr. Gwyn Bebb, Dr. W. Blahey, Dr. C. Card, Dr. S. Dowden, Dr. J. Easaw, Dr. D. Hao, Dr. Vanessa Krause, Dr. S. Lupichuk, Dr. Jose Monzon, Dr. D. Morris, Dr. A.H.G. Paterson, Dr. D. Ruether, Dr. D. Stewart, Dr. Vincent Tam, Dr. P. Tang, Dr. T. Thaeil, Dr. Roger Tsang, Dr. Mike Vickers, Dr. B. Walley,</p> <p><b>Grande Prairie</b> Dr. D. Moreau, Dr. C. Strehlke</p> <p><b>Medicine Hat</b> Dr. Marc Trudeau</p> <p><b>Red Deer</b> Dr. Naveen Basappa, Dr. Neil Graham, Dr. Callisto Tarukandirwa, Dr. John Walker</p> <p><b>Lethbridge</b> Dr. Malcolm Brigden, Dr. Faraj El-Gehani</p> <p>As recommended by the lung or GI tumour group program or outlined under group 2 drugs on first page.</p>	Feb/05  Oct/12 May/14 Jun/14  May/08  May/14	Basic

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
PERTUZUMAB	2	injectable	<p><b>Breast Cancer</b></p> <ul style="list-style-type: none"> <li>• In combination with trastuzumab and a taxane for the treatment of patients with HER2 positive unresectable locally recurrent or metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease or who have not relapsed within 6 months of receiving trastuzumab in the adjuvant setting</li> <li>• Prescribing limited to written authorization by named physicians:</li> </ul> <p><b>CCI</b>            Dr. Dick Au, Dr. Sanraj Basi, Dr. Maria Ho, Dr. Anil Joy, Dr. Karen King, Dr. John Mackey, Dr. Judith Meza-Junco            Dr. Julie Price Hiller, Dr. Andrew Scarfe,            Dr. Michael Smylie, Dr. Katia Tonkin, Dr. John Walker</p> <p><b>TBCC</b>            Dr. Vivian Bramwell, Dr. Scot Dowden, Dr. D. Heng,            Dr. Jan-Willem Henning, Dr. Vanessa Krause,            Dr. Sasha Lupichuk, Dr. Alexander Paterson,            Dr. Dean Ruether, Dr. Doug Stewart, Dr. Vincent Tam,            Dr. Patricia Tang, Dr. Roger Tsang, Dr. Barb Walley,            Dr. Marc Webster</p> <p><b>Grande Prairie</b>            Dr. Marie Moreau, Dr. Claudia Strehlke</p> <p><b>Lethbridge</b>            Dr. Malcolm Brigden, Dr. Faraj El-Gehani</p> <p><b>Medicine Hat</b>            Dr. Joshua Foley, Dr. Marc Trudeau</p> <p><b>Red Deer</b>            Dr. Naveen Basappa, Dr. Neil Graham,            Dr. Callisto Tarukandirwa, Dr. John Walker</p> <p>As recommended by the breast tumour program or outlined under group 2 drugs on first page.</p>	Dec/13	advanced
PREDNISOLONE SODIUM PHOSPHATE	1	liquid		Nov/96 Apr/09	n/a
PREDNISON	1	tablets			n/a
PROCARBAZINE	1	capsules		Oct/05 Apr/09	n/a
RALTITREXED	1	injectable		Jul/97 Mar/03 Apr/09	IV inf. – basic

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
RITUXIMAB	2	injectable	<p><b>Hematology / Lymphoma</b></p> <ul style="list-style-type: none"> <li>Rituximab plus chemotherapy for patients with follicular, mantle cell, and other CD20+ indolent histology non-Hodgkin's lymphoma who have had no prior treatment with Rituximab</li> <li>Relapsed or refractory, low-grade or follicular, CD20 positive, B-cell, non-Hodgkin's lymphoma.</li> <li>In combination with chemotherapy for aggressive histology B-cell CD20 positive non-Hodgkin's lymphoma (any age or stage).</li> <li>For Post Transplant Lymphoproliferative Disorders (PTLD).</li> <li>Maintenance Rituximab for Follicular Lymphoma patients who are in remissions (CR or PR) following chemotherapy +/- Rituxan induction.</li> <li>extended maintenance therapy for 8 doses in patients with indolent CD-20(+) B cell lymphomas who have recently (within 3 months) responded to systemic therapy and have never previously received maintenance Rituximab</li> <li>reinduction chemotherapy (including high dose therapy and ASCT) for patients with CD-20(+) Large B cell lymphomas who are in first relapse after at least a 6 month remission following initial rituximab containing chemotherapy (and who are considered potential candidate for high dose therapy and autologous stem cell transplantation (no serious co-morbidities, no CNS lymphoma)</li> <li>Rituximab in combination with chemotherapy as first-line treatment of chronic lymphocytic leukemia</li> <li>Maintenance rituximab given every two months for transplant ineligible mantle cell lymphoma patients after induction chemotherapy until progression.</li> <li>Monotherapy (after corticosteroid failure) for autoimmune cytopenias due to CLL or other indolent B-Cell lymphomas</li> <li>Monotherapy (weekly x 4 doses) as initial treatment for patients with follicular, mantle cell or other CD20+ indolent histology non-Hodgkin's lymphoma who have contraindications to, or who cannot tolerate chemotherapy.</li> <li>Prescribing limited to written authorization by named physicians:</li> </ul> <p><b>CCI</b>            Dr. N. Basappa, Dr. Sanraj Basi, Dr. Andrew Belch, Dr. Lauren Bolster, Dr. Joseph Brandwein, Dr. Neil Chua, Dr. Amelie Fontaine, Dr. Melaku Game, Dr. Marlene Hamilton, Dr. Loree Larratt, Dr. Elena Liew, Dr. Jeff Patterson, Dr. Anthea Peters, Dr. Bruce Ritchie, Dr. Lalit Saini, Dr. Irwindeep Sandhu, Dr. Randeep Sangha, Dr. Minakshi Taparia, Dr. A. Robert Turner, Dr. Chris Venner, Dr. Cynthia Wu, Dr. Nancy Zhu</p> <p><b>TBCC</b>            Dr. Nizar Bahlis, Dr. Walter Blahey, Dr. Chris Brown, Dr. Andrew Daly, Dr. P. Duggan, Dr. Michelle Geddes, Dr. Dawn Goodyear, Dr. Jennifer Grossman, Dr. Deirdre Jenkins, Dr. Johannes Lategan, Dr. Adrienne Lee, Dr. Ernesta Paola Neri, Dr. Carolyn Owen, Dr. Natalia Rydz, Dr. Mary Lynn Savoie, Dr. M. Shafey, Dr. Jiri Slaby, Dr. Doug Stewart, Dr. J. Storek, Dr. Lesley Street, Dr. J.F. Ted Thaell, Dr. Karen Valentine, Dr. M. Wong, Dr. J. Yau, Dr. Victor Zepeda</p> <p><b>Grande Prairie</b>            Dr. Marie Moreau, Dr. Claudia Strehlke</p> <p><b>Lethbridge</b>            Dr. Stanley Benke, Dr. Malcolm Brigden,            Dr. Faraj El-Gehani</p> <p><b>Medicine Hat</b>            Dr. Marc Trudeau</p> <p><b>Red Deer</b>            Dr. Neil Graham, Dr. Kathryn Rudolph,            Dr. Callisto Tarukandirwa</p> <p>As recommended by the hematology/lymphoma tumour program or outlined under group 2 drugs on first page.</p>	Sept/04  Jan/00  Mar/01 May/04 Apr/12  Apr/03  Mar/07  May/08   May/10 Apr/12   Jan/12  July/13  July/13	IV – advanced

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
RUXOLITINIB	2	oral	<p><b>Hematology</b></p> <ul style="list-style-type: none"> <li>For patients with intermediate to high risk symptomatic Myelofibrosis (MF) as assessed using the Dynamic International Prognostic Scoring System (DIPSS) Plus or patients with symptomatic splenomegaly. Patients who have ECOG performance status <math>\leq 3</math> and be either previously untreated or refractory to other treatment.</li> <li>Prescribing limited to written authorization by named physicians:</li> </ul> <p><b>CCI</b>            Dr. N. Basappa, Dr. Sanraj Basi, Dr. Andrew Belch, Dr. Lauren Bolster, Dr. Joseph Brandwein, Dr. Neil Chua, Dr. Amelie Fontaine, Dr. Melaku Game, Dr. Marlene Hamilton, Dr. Loree Larratt, Dr. Elena Liew, Dr. Jeff Patterson, Dr. Anthea Peters, Dr. Bruce Ritchie, Dr. Lalit Saini, Dr. Irwindeep Sandhu, Dr. Randeep Sangha, Dr. Minakshi Taparia, Dr. A. Robert Turner, Dr. Chris Venner, Dr. Cynthia Wu, Dr. Nancy Zhu</p> <p><b>TBCC</b>            Dr. Nizar Bahlis, Dr. Walter Blahey, Dr. Chris Brown, Dr. Andrew Daly, Dr. P. Duggan, Dr. Michelle Geddes, Dr. Dawn Goodyear, Dr. Jennifer Grossman, Dr. Deirdre Jenkins, Dr. Johannes Lategan, Dr. Adrienne Lee, Dr. Ernesta Paola Neri, Dr. Carolyn Owen, Dr. Natalia Rydz, Dr. Mary Lynn Savoie, Dr. M. Shafey, Dr. Jiri Slaby, Dr. Doug Stewart, Dr. J. Storek, Dr. Lesley Street, Dr. J.F. Ted Thael, Dr. Karen Valentine, Dr. M. Wong, Dr. J. Yau, Dr. Victor Zepeda</p> <p><b>Grande Prairie</b>            Dr. Marie Moreau, Dr. Claudia Strehlke</p> <p><b>Lethbridge</b>            Dr. Stanley Benke, Dr. Malcolm Brigden, Dr. Faraj El-Gehani</p> <p><b>Medicine Hat</b>            Dr. Marc Trudeau</p> <p><b>Red Deer</b>            Dr. Neil Graham, Dr. Kathryn Rudolph, Dr. Callisto Tarukandirwa</p> <p>As recommended by the hematology/lymphoma tumour program or outlined under group 2 drugs on first page.</p>	Oct/13	n/a

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
SORAFENIB	2	tablets	<p><b>Advanced Hepatocellular Carcinoma</b></p> <ul style="list-style-type: none"> <li>• For patients with Child Pugh Class A advanced hepatocellular carcinoma,</li> <li>• Have ECOG status 0, 1, or 2; and</li> <li>• Patients who have either progressed on trans-arterial chemoembolization (TACE) or are not suitable for the TACE procedure</li> <li>• Prescribing limited to written authorization by named physicians:</li> </ul> <p><b>CCI</b>                      Dr. Naveen Basappa, Dr. Charles Butts, Dr. Neil Chua, Dr. A.L.A. Fields, Dr. Amelie Fontaine, Dr. Maria Ho, Dr. Karen King, Dr. Sheryl Koski, Dr. Karen Mulder, Dr. Julie Price Hiller, Dr. Michael Sawyer, Dr. Andrew Scarfe, Dr. Jennifer Spratlin, Dr. John Walker                      Dr. Clarence Wong</p> <p><b>TBCC</b>                      Dr. Gwyn Bebb, Dr. Walter Blahey, Dr. Tina Cheng, Dr. Scot Dowden, Dr. Jay Easaw, , Dr. Vanessa Krause, Dr. Sasha Lupichuk, Dr. Jose Monzon, Dr. Don Morris, Dr. Sandy Paterson, Dr. Dean Ruether, Dr. Doug Stewart, Dr. Vincent Tam, Dr. P. Tang, Dr. Ted Thaell, Dr. Mike Vickers, Dr. Barb Walley</p> <p><b>Lethbridge</b>                      Dr. Malcolm Brigden, Dr. Faraj El-Gehani</p> <p><b>Grande Prairie</b>                      Dr. Marie Moreau, Dr. Claudia Strehlke</p> <p><b>Medicine Hat</b>                      Dr. Marc Trudeau</p> <p><b>Red Deer</b>                      Dr. Naveen Basappa, Dr. Neil Graham, Dr. Callisto Tarukandirwa, Dr. John Walker                      As recommended by the GI tumour program or outlined under group 2 drugs on first page</p>	Apr/09	n/a
			<p><b>Renal</b></p> <ul style="list-style-type: none"> <li>• as second line treatment (after failure of cytokine therapy) for advanced/Metastatic renal cell carcinoma</li> <li>• Prescribing limited to written authorization by named physicians:</li> </ul> <p><b>CCI</b>                      Dr. Naveen Basappa, Dr. Scott North, Dr. Peter Venner</p> <p><b>TBCC</b>                      Dr. Tina Cheng, Dr. D. Heng, Dr. Dean Ruether, Dr. Vincent Tam, Dr. Mike Vickers</p> <p><b>Grande Prairie</b>                      Dr. Marie Moreau, Dr. Claudia Strehlke</p> <p><b>Lethbridge</b>                      Dr. Malcolm Brigden, Dr. Faraj El-Gehani</p> <p><b>Medicine Hat</b>                      Dr. Marc Trudeau</p> <p><b>Red Deer</b>                      Dr. Naveen Basappa, Dr. Neil Graham, Dr. Callisto Tarukandirwa, Dr. John Walker                      As recommended by the GU tumour program or outlined under group 2 drugs on first page.</p>	Oct/09	
STREPTOZOCIN	1	injectable		May/85	IV inf. – basic

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
SUNITINIB	2	capsule	<p><b><u>Musculoskeletal</u></b></p> <ul style="list-style-type: none"> <li>Metastatic or unresectable Gastrointestinal Stromal Tumour (GIST) after disease progression on or after intolerance to imatinib</li> <li>Prescribing limited to written authorization by named physicians:</li> </ul> <p><b>CCI</b> Dr. Quincy Chu, Dr. Karen Mulder, Dr. S. Mckillop, Dr. A. Robert Turner</p> <p><b>TBCC</b> Dr. Vivian Bramwell, Dr. Jan-Willem Henning, Dr. Don Morris, Dr. Vincent Tam, Dr. Mike Vickers</p> <p><b>Medicine Hat</b> Dr. Marc Trudeau</p> <p><b>Lethbridge</b> Dr. Malcolm Brigden, Dr. Faraj El-Gehani</p> <p><b>Red Deer</b> Dr. Naveen Basappa, Dr. Callisto Tarukandirwa, Dr. John Walker</p> <p>As recommended by the musculoskeletal tumour program or outlined under group 2 drugs on first page.</p>	Oct/07	n/a
			<p><b><u>Renal</u></b></p> <ul style="list-style-type: none"> <li>First line in advanced/metastatic renal cell carcinoma or second line after interferon failure/intolerance or if patients unable to tolerate ongoing first line pazopanib. Not to be used after progression on pazopanib.</li> <li>Prescribing limited to written authorization by named physicians:</li> </ul> <p><b>CCI</b> Dr. Naveen Basappa, Dr. Scott North, Dr. Peter Venner</p> <p><b>TBCC</b> Dr. Tina Cheng, Dr. D. Heng, Dr. Dean Ruether, Dr. Vincent Tam, Dr. Mike Vickers</p> <p><b>Grande Prairie</b> Dr. Marie Moreau, Dr. Claudia Strehlke</p> <p><b>Lethbridge</b> Dr. Malcolm Brigden, Dr. Faraj El-Gehani</p> <p><b>Medicine Hat</b> Dr. Marc Trudeau</p> <p><b>Red Deer</b> Dr. Naveen Basappa, Dr. Neil Graham, Dr. Callisto Tarukandirwa, Dr. John Walker</p> <p>As recommended by the GU tumour program or outlined under group 2 drugs on first page.</p>	Feb/08 Mar/14	n/a



Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
SUNITINIB	2	capsule	<p><b>pNET</b></p> <ul style="list-style-type: none"> <li>for the treatment of patients with unresectable locally advanced or metastatic well-differentiated pancreatic endocrine tumors (pancreatic NET) whose disease is progressive and who have not previously been treated with everolimus (unless intolerant).</li> <li>Prescribing limited to written authorization by named physicians:</li> </ul> <p><b>CCI</b>                      Dr. N Basappa, Dr. C Butts, Dr. N Chua, Dr. M Ho                      Dr. K King, Dr. S Koski, Dr. J Meza-Junco, Dr. K Mulder,                      Dr. J Price Hiller, Dr. M Sawyer, Dr. A Scarfe,                      Dr. J Spratlin, Dr. C Wong</p> <p><b>TBCC</b>                      Dr. C Card, Dr. JD Ruether, Dr. S Dowden</p> <p><b>Grande Prairie</b>                      Dr. M Moreau, Dr. C Strehlke</p> <p><b>Lethbridge</b>                      Dr. M Brigden, Dr. F El-Gehani</p> <p><b>Medicine Hat</b>                      Dr. M Trudeau</p> <p><b>Red Deer</b>                      Dr. Naveen Basappa, Dr. Neil Graham,                      Dr. Callisto Tarukandirwa, Dr. John Walker</p> <p>As recommended by the endocrine or gastrointestinal tumor program</p>	Mar/13	n/a
TAMOXIFEN	1	tablets		Jul/92	n/a
TEMOZOLOMIDE	2	oral	<p><b>NeuroOncology and Pediatrics</b></p> <ul style="list-style-type: none"> <li>First-line concurrent (with RT)/adjuvant treatment for malignant glioma</li> <li>First-line treatment of recurrent glioblastoma multiforme and anaplastic astrocytoma.</li> <li>For dose intensive RESCUE protocol for relapsed malignant gliomas</li> <li>Prescribing limited to written authorization by named physicians:</li> </ul> <p><b>CCI</b>                      Dr. Dorcas Fulton, Dr. Albert Murtha, Dr. Wilson Roa,                      Dr. Peter Venner</p> <p><b>TBCC</b>                      Dr. J.G. Cairncross, Dr. Paula deRobles, Dr. Jay Easaw,                      Dr. Don Morris, Dr. Alexander Paterson, Dr. Roger Tsang                      As recommended by the neuro oncology tumour program or outlined under group 2 drugs on first page.</p> <p>Or</p> <p><b>CCI</b>                      Dr. Sunil Desai, Dr. Paul Grundy, Dr. M. Spavor,                      Dr. Kent Stobart, Dr. Beverly Wilson</p> <p><b>TBCC</b>                      Dr. Ron A. Anderson, Dr. G. Guilcher, Dr. L. Lafay-Cousin,                      Dr. Victor Lewis, Dr. Aru Narendran, Dr. Douglas Strother                      As recommended by the pediatric tumour program or outlined under group 2 drugs on first page.</p>	Sept/04 Feb/00 Jun/11	n/a

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
TEMOZOLOMIDE	2	oral	<p><b>Pediatrics</b></p> <ul style="list-style-type: none"> <li>Phase III study of irinotecan and temozolomide in children with recurrent neuroblastoma (protocol ANBL0421)</li> <li>Prescribing limited to written authorization by named physicians:</li> </ul> <p><b>CCI</b> Dr. Sunil Desai, Dr. Paul Grundy, Dr. M. Spavor, Dr. Kent Stobart, Dr. Beverly Wilson</p> <p><b>TBCC</b> Dr. Ron A. Anderson, Dr. G. Guilcher, Dr. L. Lafay-Cousin, Dr. Victor Lewis, Dr. Aru Narendran, Dr. Douglas Strother, As recommended by the pediatric tumour program.</p>	Jan/08	n/a
TEMSIROLIMUS	2	injectable		Nov/10 Jun/14	IV-basic
TENIPOSIDE	1	injectable		May/85	IV inf. – basic
THIOGUANINE	1	tablets			n/a
TOPOTECAN	1	injectable		Jul/97 Apr/09	IV inf. – basic
TRASTUZUMAB	2	injectable	<p><b>Metastatic Breast</b></p> <ul style="list-style-type: none"> <li>Restricted to the treatment of metastatic breast cancer, HER 2 protein overexpression (+3) by IHC or HER2 amplification by FISH.</li> <li>For the 2nd line treatment of HER2 positive metastatic breast cancer when used in combination with chemotherapy after previous exposure to trastuzumab-base treatments in the metastatic setting.</li> <li>Prescribing limited to written authorization by named physicians:</li> </ul> <p><b>CCI</b> Dr. Dick Au, Dr. Sanraj Basi, Dr. Maria Ho, Dr. Anil Joy, Dr. Karen King, Dr. John Mackey, Dr. Judith Meza-Junco, Dr. Julie Price Hiller, Dr. Andrew Scarfe, Dr. Michael Smylie, Dr. Katia Tonkin, Dr. John Walker</p> <p><b>TBCC</b> Dr. Vivian Bramwell, Dr. Scot Dowden, Dr. D. Heng, Dr. Jan-Willem Henning, Dr. Vanessa Krause, Dr. Sasha Lupichuk, Dr. Alexander Paterson, Dr. Dean Ruether, Dr. Doug Stewart, Dr. Vincent Tam, Dr. Patricia Tang, Dr. Roger Tsang, Dr. Barb Walley, Dr. Marc Webster</p> <p><b>Grande Prairie</b> Dr. Marie Moreau, Dr. Claudia Strehlke</p> <p><b>Lethbridge</b> Dr. Malcolm Brigden, Dr. Faraj El-Gehani</p> <p><b>Medicine Hat</b> Dr. Joshua Foley, Dr. Marc Trudeau</p> <p><b>Red Deer</b> Dr. Naveen Basappa, Dr. Neil Graham, Dr. Callisto Tarukandirwa, Dr. John Walker As recommended by the breast tumour program or outlined under group 2 drugs on first page.</p>	Jan/00 Feb/02 Nov/03  Feb/12	IV load dose - advanced IV maintenance (2mg/kg weekly or 6mg/kg every 3 weeks) – basic

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
TRASTUZUMAB	2	injectable	<p><b>Breast Cancer</b></p> <ul style="list-style-type: none"> <li>• Adjuvant/Neoadjuvant treatment of Stage 1-3, HER-2 positive breast cancer for use with or following chemotherapy</li> <li>• Prescribing limited to written authorization by named physicians:</li> </ul> <p><b>CCI</b>            Dr. Dick Au, Dr. Sanraj Basi, Dr. Maria Ho, Dr. Anil Joy, Dr. Karen King, Dr. John Mackey, Dr. Judith Meza-Junco            Dr. Julie Price Hiller, Dr. Andrew Scarfe,            Dr. Michael Smylie, Dr. Katia Tonkin, Dr. John Walker</p> <p><b>TBCC</b>            Dr. Vivian Bramwell, Dr. Scot Dowden, Dr. D. Heng, Dr. Jan-Willem Henning, Dr. Vanessa Krause,            Dr. Sasha Lupichuk, Dr. Alexander Paterson,            Dr. Dean Ruether, Dr. Doug Stewart, Dr. Vincent Tam,            Dr. Patricia Tang, Dr. Roger Tsang, Dr. Barb Walley,            Dr. Marc Webster</p> <p><b>Grande Prairie</b>            Dr. Marie Moreau, Dr. Claudia Strehlke</p> <p><b>Lethbridge</b>            Dr. Malcolm Brigden, Dr. Faraj El-Gehani</p> <p><b>Medicine Hat</b>            Dr. Joshua Foley, Dr. Marc Trudeau</p> <p><b>Red Deer</b>            Dr. Naveen Basappa, Dr. Neil Graham,            Dr. Callisto Tarukandirwa, Dr. John Walker</p> <p>As recommended by the breast tumour program or outlined under group 2 drugs on first page.</p>	Aug/06	Basic
			<p><b>Metastatic Gastroesophageal Cancer</b></p> <ul style="list-style-type: none"> <li>• Trastuzumab in conjunction with Cisplatin and either 5-Fluorouracil or Capecitabine as palliative treatment for advanced adenocarcinoma of the stomach and gastroesophageal junction that demonstrates HER2 over-expression (immunohistochemistry score 3+ or 2+ with in situ hybridization positivity).</li> <li>• Prescribing limited to written authorization by named physicians:</li> </ul> <p><b>CCI</b>            Dr. Naveen Basappa, Dr. Charles Butts, Dr. Neil Chua, Dr. A.L.A. Fields, Dr. Amelie Fontaine, Dr. Maria Ho, Dr. Karen King, Dr. Sheryl Koski, Dr. Karen Mulder, Dr. Julie Price Hiller, Dr. Michael Sawyer, Dr. Andrew Scarfe, Dr. Jennifer Spratlin, Dr. John Walker            Dr. Clarence Wong</p> <p><b>TBCC</b>            Dr. Gwyn Bebb, Dr. Walter Blahey, Dr. Tina Cheng, Dr. Scot Dowden, Dr. Jay Easaw, , Dr. Vanessa Krause, Dr. Sasha Lupichuk, Dr. Jose Monzon, Dr. Don Morris, Dr. Sandy Paterson, Dr. Dean Ruether, Dr. Doug Stewart, Dr. Vincent Tam, Dr. P. Tang, Dr. Ted Thaell,            Dr. Mike Vickers, Dr. Barb Walley</p> <p><b>Grande Prairie</b>            Dr. Marie Moreau, Dr. Claudia Strehlke</p> <p><b>Medicine Hat</b>            Dr. Josh Foley, Dr. Marc Trudeau</p> <p><b>Red Deer</b>            Dr. Naveen Basappa, Dr. Neil Graham,            Dr. Callisto Tarukandirwa, Dr. John Walker</p> <p><b>Lethbridge</b>            Dr. Malcolm Brigden, Dr. Faraj El-Gehani</p> <p>As recommended by the GI tumour group or outlined under group 2 drugs on first page.</p>	Aug/12	IV load dose - advanced IV maintenance (6mg/kg every 3 weeks) – basic

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
TRASTUZUMAB EMTANSINE (KADCYLA)	2	injectable	<p><b>Breast Cancer</b></p> <ul style="list-style-type: none"> <li>In the second line setting for patients with HER2-positive unresectable locally advanced or metastatic breast cancer. Patients should be ECOG performance status of 0 or 1. Patients must have received prior treatment with Trastuzumab plus chemotherapy (+/- pertuzumab) in the metastatic setting or have disease recurrence during or within 6 months of completing adjuvant therapy with Trastuzumab plus chemotherapy (+/- pertuzumab).</li> <li>Prescribing limited to written authorization by named physicians:</li> </ul> <p><b>CCI</b> Dr. Dick Au, Dr. Sanraj Basi, Dr. Maria Ho, Dr. Anil Joy, Dr. Karen King, Dr. John Mackey, Dr. Judith Meza-Junco, Dr. Julie Price Hiller, Dr. Andrew Scarfe, Dr. Michael Smylie, Dr. Katia Tonkin, Dr. John Walker</p> <p><b>TBCC</b> Dr. Vivian Bramwell, Dr. Scot Dowden, Dr. D. Heng, Dr. Jan-Willem Henning, Dr. Vanessa Krause, Dr. Sasha Lupichuk, Dr. Alexander Paterson, Dr. Dean Ruether, Dr. Doug Stewart, Dr. Vincent Tam, Dr. Patricia Tang, Dr. Roger Tsang, Dr. Barb Walley, Dr. Marc Webster</p> <p><b>Grande Prairie</b> Dr. Marie Moreau, Dr. Claudia Strehlke</p> <p><b>Lethbridge</b> Dr. Malcolm Brigden, Dr. Faraj El-Gehani</p> <p><b>Medicine Hat</b> Dr. Joshua Foley, Dr. Marc Trudeau</p> <p><b>Red Deer</b> Dr. Naveen Basappa, Dr. Neil Graham, Dr. Callisto Tarukandirwa, Dr. John Walker</p> <p>As recommended by the breast tumour program or outlined under group 2 drugs on first page.</p>	Jun/14	basic
TRETINOIN	1	capsules		May/95 Apr/09	n/a
VEMURAFENIB	2	oral	<p><b>Melanoma</b></p> <ul style="list-style-type: none"> <li>treatment of BRAF V600 mutation – positive unresectable or metastatic melanoma</li> <li>Prescribing limited to written authorization by named physicians:</li> </ul> <p><b>CCI</b> Dr. Michael Smylie, Dr. John Walker</p> <p><b>TBCC</b> Dr. Tina Cheng, Dr. Jose Monzon</p> <p>As recommended by the cutaneous tumour program or outlined under group 2 drugs on first page</p>	Oct/12	n/a
VINBLASTINE	1	injectable			IV push - basic
VINCRISTINE	1	injectable			IV push – basic
VINORELBINE	1	injectable		Jul/95 Apr/09	IV inf. - basic

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
VISMODEGIB	2	Oral	<ul style="list-style-type: none"> <li>• For the treatment of metastatic basal cell carcinoma (BCC) or locally advanced BCC (including patients with basal cell nevus syndrome, i.e., Gorlin syndrome) in patients who meet the following criteria:               <ul style="list-style-type: none"> <li>- patients must have measurable metastatic disease or locally advanced disease; AND</li> <li>- patients' disease must be considered inoperable or inappropriate for surgery; AND</li> <li>- patients' disease must be considered inappropriate for radiotherapy, AND</li> <li>- patient is 18 year of age or older, AND</li> <li>- patient has an EGOG≤2</li> </ul> </li> </ul> <p>Dose is 150 mg orally once daily taken until disease progression or unacceptable toxicity. Physicians must provide rationale for why surgery AND radiation cannot be considered</p> <ul style="list-style-type: none"> <li>- must include a surgical consult note that provides a preoperative/surgical evaluation why surgery is not appropriate for the patient; AND</li> <li>- a consult note as to why radiation therapy is not appropriate for the patient: AND</li> <li>- both of the above evaluations must come from a physician who is not the ordering physician, AND</li> <li>- the chart must include confirmation that the patient has been discussed at a multi-disciplinary cancer conference (MCC) or equivalent.</li> </ul> <p>Note: considered inoperable or inappropriate for surgery for at least ONE of the following reasons:</p> <ul style="list-style-type: none"> <li>- technically not possible to perform surgery due to size/location/invasiveness of BCC (either lesion too large or can be several small lesions making surgery not feasible) OR</li> <li>- recurrence of BCC after two or more surgical procedures and curative resection unlikely; OR</li> <li>- substantial deformity and/or morbidity anticipated from surgery</li> </ul> <p>Note: considered inappropriate for radiation for at least ONE of the following reasons:</p> <ul style="list-style-type: none"> <li>- contraindication to radiation (e.g. Gorlin syndrome) OR</li> <li>- prior radiation lesion: OR</li> <li>- suboptimal outcomes expected due to size/location/invasiveness of BCC</li> </ul> <p>Note: patients preference for oral therapy will not be considered</p> <ul style="list-style-type: none"> <li>• Prescribing limited to named physicians WHO ARE REGISTERED IN EPPP PROGRAM WITH A SPECIFIC PRESCRIBER ID NUMBER:</li> </ul> <p><b>CCI</b> Dr. Michael Smylie, Dr. John Walker</p> <p><b>TBCC</b> Dr. Tina Cheng, Dr. Jose Monzon</p> <p>As recommended by the cutaneous tumour program or outlined under group 2 drugs on first page</p>	Jun/14	basic